On this page
Quick Reference
Overview and Recommendations
Background
- •Hypoglycemia affects up to 10% of hospitalized patients and is the most common metabolic emergency in diabetes, with severe episodes carrying a 2-fold increased risk of cardiovascular events and a 3-fold increase in mortality in type 2 diabetes. The American Diabetes Association (ADA) classifies hypoglycemia into three levels: Level 1 (alert value ≤70 mg/dL or 3.9 mmol/L), Level 2 (clinically significant <54 mg/dL or 3.0 mmol/L), and Level 3 (severe, requiring external assistance regardless of glucose level). This tiered system replaced older symptom-based definitions and now anchors clinical decision-making, trial endpoints, and reimbursement criteria.
- •More than 95% of clinically significant hypoglycemia is iatrogenic in patients with diabetes, driven by insulin or sulfonylurea therapy. In type 1 diabetes, severe hypoglycemia rates are approximately 100-130 episodes per 100 patient-years, while in insulin-treated type 2 diabetes the rate is 10-30 per 100 patient-years. Among non-diabetic populations, insulinoma is the most common endogenous cause of hyperinsulinemic hypoglycemia, with an incidence of 1-4 per million person-years, and is malignant in 5-10% of cases. Congenital hyperinsulinism (CHI) affects 1 in 25,000-50,000 live births, with mutations in ABCC8 and KCNJ11 accounting for the majority.
- •The counter-regulatory axis, insulin, glucagon, epinephrine, cortisol, and growth hormone, normally maintains plasma glucose within a narrow range. Maladaptive failure of this axis underlies all hypoglycemia: excess insulin or insulin-like activity (e.g., insulinoma, sulfonylurea overdose, non-islet cell tumor hypoglycemia), deficient counter-regulation (e.g., adrenal insufficiency, growth hormone deficiency, long-standing type 1 diabetes with loss of glucagon response), and altered substrate availability (e.g., liver failure, renal failure, inborn errors of metabolism, alcohol ingestion). The biochemical signature, measured by paired insulin, C-peptide, proinsulin, and beta-hydroxybutyrate, fingerprints the specific lesion.
- •Post-bariatric hypoglycemia (PBH), most common after Roux-en-Y gastric bypass, affects an estimated 10-30% of patients and results from rapid nutrient delivery causing exaggerated GLP-1 secretion and reactive hyperinsulinemia 1-3 hours after meals. Insulin autoimmune syndrome (Hirata disease), mediated by anti-insulin antibodies, is more common in Asian populations and often triggered by sulfhydryl-group medications. Type B insulin resistance syndrome, caused by autoantibodies to the insulin receptor, paradoxically presents with severe hypoglycemia in a subset of patients. Recognizing these syndromic contexts is essential for targeted therapy.
- •The landmark NICE-SUGAR trial (2009) demonstrated that intensive glucose control (target 81-108 mg/dL) in critically ill patients increased mortality compared with a liberal target (<180 mg/dL) (HR 1.14, 95% CI 1.02-1.28), establishing that hypoglycemia prevention is as important as hyperglycemia management. Similarly, the ACCORD trial (2008) showed that intensive HbA1c lowering to <6.0% in type 2 diabetes increased all-cause mortality (HR 1.22, 95% CI 1.01-1.46), driven in part by severe hypoglycemia. These trials reshaped glycemic targets worldwide, emphasizing individualized goals and the need for safer therapeutic strategies.
Evaluation
- •Suspect hypoglycemia in any patient with altered mental status, diaphoresis, palpitations, tremor, or unexplained weakness, especially those with diabetes on insulin or sulfonylureas, or in the setting of critical illness, renal failure, or alcohol use. Classic Whipple's triad (symptoms + low glucose + relief with glucose) is the diagnostic gatekeeper; without it, further workup is not indicated.
- •Ask about timing and context: fasting versus postprandial symptoms, relation to meals or exercise, missed meals, alcohol ingestion, and any recent changes in medication doses or timing. In patients with diabetes, review the insulin or sulfonylurea regimen in detail, including type, dose, timing, and injection technique. For nocturnal hypoglycemia, ask about night sweats, morning headache, or confusional arousals.
- •Examine for autonomic signs (tachycardia, hypertension, diaphoresis, piloerection) and neuroglycopenic signs (confusion, slurred speech, ataxia, focal neurological deficits mimicking stroke, seizures, or coma). Perform a full neurological exam: mental status, cranial nerves (pupils, extraocular movements, speech), motor strength, sensation, reflexes (hyperreflexia, Babinski sign), and coordination. Check for acanthosis nigricans (suggesting type B insulin resistance syndrome) and hepatomegaly (glycogen storage disease or lymphoma).
- •Obtain a bedside capillary glucose immediately using a point-of-care glucometer. If glucose <70 mg/dL (3.9 mmol/L), confirm with a venous or arterial sample for accurate diagnosis; note that capillary glucose may lag in shock or peripheral edema. In any patient with altered mental status or focal neurological deficits, especially in the emergency department, check a bedside glucose before imaging; hypoglycemia can mimic acute stroke.
- •At the time of documented hypoglycemia (glucose <54 mg/dL [3.0 mmol/L]), draw a critical sample: plasma glucose, insulin, C-peptide, proinsulin, beta-hydroxybutyrate (BOHB), and a screen for sulfonylureas and meglitinides. This paired-hormone analysis is the cornerstone of etiologic diagnosis. Suppressed BOHB (<2.7 mmol/L) indicates insulin-mediated hypoglycemia; elevated BOHB points to counter-regulatory failure or substrate deficiency.
- •A insulin ≥3 μIU/mL (18 pmol/L) with C-peptide ≥0.6 ng/mL (0.2 nmol/L) and proinsulin ≥5 pmol/L defines endogenous hyperinsulinism (e.g., insulinoma, sulfonylurea overdose, insulin autoimmune syndrome). If C-peptide is low (<0.6 ng/mL) in the setting of high insulin, suspect exogenous insulin administration (factitious use). A negative sulfonylurea screen on a contemporaneous sample is essential to rule out surreptitious use.
- •If spontaneous hypoglycemia is not captured and fasting hypoglycemia is suspected, perform a supervised 72-hour fast in a controlled inpatient setting. Measure plasma glucose every 4-6 hours; when glucose falls below 60 mg/dL (3.3 mmol/L), measure hourly. Terminate the fast when: glucose <45 mg/dL (2.5 mmol/L) with symptoms, glucose <50 mg/dL (2.8 mmol/L) without symptoms after 72 hours, or neuroglycopenic symptoms develop. At termination, draw the critical sample. The 72-hour fast has a sensitivity of approximately 95% for insulinoma.
- •For patients with postprandial symptoms (occurring 2-4 hours after meals), perform a 5-hour mixed-meal test (not an oral glucose tolerance test, which can provoke dumping syndrome). The patient consumes a standardized mixed meal; glucose, insulin, and C-peptide are measured every 30 minutes. A positive test requires reproduction of symptoms with a glucose <55 mg/dL (3.0 mmol/L) and concomitant elevated insulin/C-peptide. This pattern is characteristic of post-bariatric hypoglycemia and early type 2 diabetes.
- •Once biochemical confirmation of endogenous hyperinsulinism is established, localize the insulinoma. First-line imaging: contrast-enhanced triple-phase CT (pancreatic protocol) or endoscopic ultrasound (EUS) with fine-needle aspiration, CT sensitivity 70-80%, EUS sensitivity 80-90%. If negative, proceed to GLP-1 receptor PET/CT (68Ga-exendin-4 or 18F-exendin-4), which detects 95% of insulinomas. For occult tumors, selective arterial calcium stimulation with hepatic venous sampling (SACST) remains the gold standard: a >2-fold rise in hepatic vein insulin after calcium injection localizes the tumor to the corresponding pancreatic region.
- •In children with congenital hyperinsulinism, obtain 18F-DOPA PET/CT to distinguish focal from diffuse disease; this determines surgical approach (focal = localized resection with high cure rate; diffuse = may require near-total pancreatectomy). Genetic testing for ABCC8, KCNJ11, GCK, GLUD1, HNF4A, and HADH is indicated in all infants with persistent hyperinsulinemic hypoglycemia.
- •When insulin and C-peptide are both suppressed, evaluate for non-islet cell tumor hypoglycemia (NICTH): measure total IGF-1, total IGF-2, and the high-molecular-weight 'big' IGF-2. A ratio of big IGF-2 to total IGF-2 >0.2 is diagnostic. Also consider adrenal insufficiency (morning cortisol <3 μg/dL [83 nmol/L] or poor response to cosyntropin 250 μg), growth hormone deficiency (low IGF-1 with low GH), and inborn errors of metabolism (fasting hypoglycemia with lactic acidosis, ketosis, or fatty liver).
- •Continuous glucose monitoring (CGM) is recommended for all individuals with diabetes at high risk for hypoglycemia, particularly those with a history of Level 3 events or hypoglycemia unawareness. CGM metrics, time below range (TBR) <70 mg/dL (<4% of time) and <54 mg/dL (TBR2), independently predict future severe hypoglycemia; each 1% increase in TBR2 is associated with a 15% higher relative risk (HR 1.15, 95% CI 1.08-1.23).
Management
- •For acute mild-to-moderate hypoglycemia in a conscious patient able to swallow, administer 15-20 g of oral glucose, 3-4 glucose tablets, 4-6 oz (120-180 mL) fruit juice, or 1 tablespoon (15 g) sugar dissolved in water. Recheck capillary glucose in 15 minutes; if still <70 mg/dL (3.9 mmol/L), repeat the same dose. This 'Rule of 15' is the cornerstone of acute self-management.
- •For severe hypoglycemia (altered mental status, seizure, or unconsciousness), administer glucagon 1 mg intramuscularly (IM), subcutaneously (SC), or intravenously (IV), 0.5 mg for children <25 kg or <5 years old. Onset of action is 5-15 minutes. Alternatively, give IV dextrose 50% (D50) 25 g (50 mL) in adults, or 0.5-1 g/kg as D25 (2 mL/kg) in children; onset is 1-3 minutes. Glucagon is preferred in out-of-hospital settings because it does not require IV access.
- •After initial correction, recheck glucose every 15 minutes until stable >70 mg/dL, then every 1-2 hours for 4-6 hours to detect recurrence. In hospitalized patients, continuous glucose monitoring (CGM) reduces time spent in hypoglycemia compared with point-of-care testing alone; the TIGHT trial (2025) showed non-ICU patients had increased time in range without increased severe hypoglycemia.
- •If glucose remains <70 mg/dL after two doses of dextrose or glucagon, initiate a continuous IV dextrose infusion, D10 at 50-100 mL/h, titrated to maintain glucose 100-150 mg/dL (5.6-8.3 mmol/L). For suspected sulfonylurea overdose, administer octreotide 50-100 mcg SC or IV every 6-12 hours to suppress endogenous insulin secretion; octreotide blocks calcium-dependent insulin release and can prevent recurrent hypoglycemia for 6-12 hours per dose.
- •Once glucose is stable >70 mg/dL for 4-6 hours, transition to oral carbohydrates and resume the patient’s usual diabetes medications with appropriate dose reductions, typically reduce insulin doses by 20-50% depending on severity of the precipitating event. Provide education on sick-day rules, medication adjustment, and the importance of never skipping meals.
- •For long-term prevention in insulin-treated type 2 diabetes, optimize the regimen: consider switching from sulfonylureas to safer agents (DPP-4 inhibitors, SGLT2 inhibitors, or GLP-1 receptor agonists) to reduce hypoglycemia risk. In type 1 diabetes, a hybrid closed-loop (automated insulin delivery, AID) system reduces HbA1c by 0.5-0.9 percentage points and severe hypoglycemia by 50% (RR 0.50, 95% CI 0.30-0.83) compared with conventional therapy.
- •For insulinoma (preoperative medical management): start diazoxide 3-8 mg/kg/day orally in two to three divided doses (adults: 50-75 mg twice daily, titrate up to 150-200 mg three times daily; maximum 400 mg/day). Monitor for fluid retention (requires concomitant thiazide diuretic in up to 40%), hirsutism, and leukopenia. If refractory, consider pasireotide 0.6-0.9 mg SC twice daily, it reduces hypoglycemia episodes by 50-80% in case series.
- •For post-bariatric hypoglycemia (PBH) not controlled by dietary modification (low glycemic index meals, small frequent meals) and acarbose 50-100 mg with meals, consider avexitide (exendin-9,39) 30 mg SC twice daily. The PREVENT trial showed avexitide raised postprandial glucose nadir from 55 to 68 mg/dL and reduced hypoglycemia event rate by 67%.
- •For congenital hyperinsulinism (CHI): first-line therapy is diazoxide 5-15 mg/kg/day (maximum 20 mg/kg/day); if responsive, continue. Second-line is octreotide 5-20 μg/kg/day SC every 6-8 hours; if refractory, lanreotide 30-120 mg IM every 4 weeks. Genotype correlates with response: ABCC8/KCNJ11 mutations limited to one allele (focal disease) are more likely to respond to diazoxide than biallelic mutations (diffuse disease). For focal CHI, laparoscopic or open resection is curative in >95% of cases.
- •In critically ill patients, target glucose 140-180 mg/dL (7.8-10.0 mmol/L). Avoid intensive targets (80-110 mg/dL), NICE-SUGAR demonstrated harm (HR 1.14, 95% CI 1.02-1.28; number needed to treat [NNT] = 38 to cause one excess death). Use IV insulin infusion with frequent monitoring (hourly point-of-care or CGM) and a validated titration protocol.
- •Do not use sulfonylureas to manage hyperinsulinemic hypoglycemia, they will worsen it. Do not use prophylactic short-acting insulin in non-insulin-deficient patients. Do not discharge a patient with severe hypoglycemia without identifying the precipitating cause and providing a prevention plan. Do not use insulin to treat hypoglycemia.
- •Refer to endocrinology for: all cases of confirmed or suspected insulinoma, congenital hyperinsulinism, post-bariatric hypoglycemia refractory to dietary modification, insulin autoimmune syndrome, Type B insulin resistance syndrome, non-islet cell tumor hypoglycemia, and recurrent severe hypoglycemia of uncertain etiology. Refer to bariatric surgery for PBH refractory to medical therapy. Refer to genetics for persistent neonatal hypoglycemia or syndromic presentations (e.g., MEN1, Wolfram syndrome).
- •The Endocrine Society recommends that all patients at risk for severe hypoglycemia (those on insulin or sulfonylureas) have a glucagon prescription and a written action plan. Structured education programs (DAFNE, BGAT) reduce severe hypoglycemia rates by 50-60%. Hypoglycemia awareness restoration training, strict avoidance of hypoglycemia for 2-3 weeks, can restore counter-regulatory responses.
- •In older adults (≥65 years), de-escalate sulfonylureas and insulin if HbA1c is consistently <7.0% or if the patient has frequent hypoglycemia. Target a less stringent HbA1c (<8.0% or <8.5%) to minimize risk. Continuous glucose monitoring reduces time below range by a mean of 1.2 hours/day in this population.
- •In chronic kidney disease (CKD), reduce insulin doses by 25-50% on dialysis days; avoid sulfonylureas with long half-lives (e.g., glyburide). Use glucose-containing dialysate (100-200 mg/dL) during hemodialysis to reduce intradialytic hypoglycemia by 40% (RR 0.60, 95% CI 0.45-0.80).
- •In neonates at risk (preterm, SGA, LGA, maternal diabetes), screen blood glucose at 1, 2, 4, 6, 12, and 24 hours of life. Prophylactic 40% dextrose gel (200 mg/kg) reduces NICU admission for hypoglycemia (RR 0.73, 95% CI 0.57-0.93; NNT = 10). For persistent neonatal hypoglycemia beyond 48 hours, evaluate for hyperinsulinism and start diazoxide 5-15 mg/kg/day after baseline echocardiography to exclude pulmonary hypertension.
Board Review — High Yield
- •Whipple's triad, hypoglycemia diagnosis requires three elements: symptoms of hypoglycemia, low plasma glucose, and resolution of symptoms after glucose administration.
- •ADA Level 2 hypoglycemia, glucose <54 mg/dL (3.0 mmol/L); this is the threshold that reliably predicts neuroglycopenic symptoms and autonomic activation.
- •72-hour fast, gold standard for diagnosing insulinoma (sensitivity 95%). Terminate when glucose <45 mg/dL with symptoms or <50 mg/dL without symptoms after 72 hours.
- •Rule of 15, acute management: 15 g oral glucose, recheck in 15 minutes, repeat if still <70 mg/dL.
- •Octreotide, drug of choice for sulfonylurea overdose (50-100 mcg SC/IV q6-12h); suppresses endogenous insulin secretion.
- •Insulinoma, most common cause of endogenous hyperinsulinemic hypoglycemia in non-diabetic adults; 5-10% malignant; localized by triple-phase CT, EUS, or GLP-1 receptor PET/CT.
- •Diazoxide, first-line medical therapy for insulinoma and congenital hyperinsulinism; opens KATP channels on beta cells, inhibiting insulin release.
- •NICE-SUGAR, landmark trial showing intensive glucose control (81-108 mg/dL) in ICU increased mortality vs. liberal target (<180 mg/dL) (HR 1.14).
- •Hypoglycemia-associated autonomic failure (HAAF), recurrent hypoglycemia blunts counter-regulatory responses; strict avoidance of hypoglycemia for 2-3 weeks restores awareness.
- •ABCC8/KCNJ11 mutations, most common genetic cause of congenital hyperinsulinism; diazoxide responsiveness is genotype-dependent.
Deep Dive — Evidence Details
Definition, Classification and Axis Nomenclature
- ▸Hypoglycemia is defined by Whipple's triad and classified into three ADA levels: Level 1 (≤3.9 mmol/L), Level 2 (<3.0 mmol/L), and Level 3 (requiring assistance).
- ▸Etiologic classification distinguishes diabetic from non-diabetic causes; non-diabetic hypoglycemia is further divided into endogenous hyperinsulinism (e.g., insulinoma, post-bariatric) and non-insulin-mediated (e.g., critical illness, inborn errors).
- ▸Severe hypoglycemia (Level 3) is associated with increased cardiovascular mortality and neurodevelopmental harm in neonates, underscoring the need for prompt recognition and prevention.
Hypoglycemia is a metabolic emergency defined by a pathologically low plasma glucose concentration that produces symptoms which resolve upon glucose administration, a framework known as Whipple's triad. The American Diabetes Association (ADA) and the Endocrine Society have standardized a three-level classification system that anchors clinical decision-making and trial endpoints [1]A1c[4]B2b. Level 1 (alert value) is a glucose ≤3.9 mmol/L (70 mg/dL) that does not necessarily require immediate treatment but signals risk. Level 2 (clinically significant) is a glucose <3.0 mmol/L (54 mg/dL) that demands prompt intervention because it reliably predicts neuroglycopenic symptoms and autonomic activation. Level 3 (severe) is any episode requiring external assistance for recovery, regardless of the measured glucose level [4]B2b. This tiered system replaces older, symptom-based definitions and provides a uniform language for clinical care and research.
Also Called / Synonyms
Hypoglycemia is also referred to as low blood glucose, hypoglycemic episode, insulin shock (historical, in the context of insulin therapy), and neuroglycopenia when cognitive symptoms predominate. In neonates, the term neonatal hypoglycemia is used [21]B2b. Post-bariatric hypoglycemia is sometimes called late or [9]D5[17]B2a. Insulin autoimmune syndrome (Hirata disease) is a rare cause of hypoglycemia mediated by anti-insulin antibodies [8]C4.
Classification
Hypoglycemia is classified by etiology, timing, and severity. The etiologic framework distinguishes diabetic hypoglycemia (related to pharmacotherapy) from non-diabetic hypoglycemia, which is further subdivided into endogenous hyperinsulinism (e.g., , insulin autoimmune syndrome, post-bariatric hypoglycemia) and non-insulin-mediated hypoglycemia (e.g., critical illness, liver failure, inborn errors of metabolism, prolonged fasting) [1]A1c[6]B3b[9]D5[14]B3b[23]A1a. Timing separates fasting hypoglycemia (occurring after >6 hours without food) from postprandial hypoglycemia (within 4 hours of a meal). The table below summarizes the major etiologic categories.
| Category | Subtype | Key Examples | Associated Marker/Feature |
|---|---|---|---|
| Diabetic | Insulin-induced | Exogenous insulin, sulfonylureas, meglitinides | Low C-peptide with high insulin (exogenous) |
| Diabetic | Insulin-independent | SGLT2 inhibitors (rare) | Euglycemic ketoacidosis |
| Non-diabetic, endogenous hyperinsulinism | Insulinoma | Pancreatic beta-cell tumor | High insulin, high C-peptide, negative sulfonylurea screen |
| Non-diabetic, endogenous hyperinsulinism | Insulin autoimmune syndrome | Anti-insulin antibodies | High total insulin, low free insulin, high C-peptide |
| Non-diabetic, endogenous hyperinsulinism | Post-bariatric hypoglycemia | Roux-en-Y gastric bypass | Postprandial, high GLP-1, exaggerated insulin response |
| Non-diabetic, non-insulin-mediated | Critical illness | Sepsis, hepatic failure, renal failure | Low insulin, low C-peptide |
| Non-diabetic, non-insulin-mediated | Inborn errors of metabolism | Fasting hypoglycemia, | |
| Non-diabetic, non-insulin-mediated | Prolonged fasting | Preoperative fasting in children | Ketosis, low insulin |
Axis Nomenclature
Hypoglycemia represents a perturbation of the glucose-insulin-glucagon axis. Primary hypoglycemia arises from intrinsic beta-cell dysfunction (e.g., insulinoma, genetic hyperinsulinism). Secondary hypoglycemia results from impaired counterregulation (e.g., liver failure, adrenal insufficiency, glucagon deficiency). Tertiary hypoglycemia is iatrogenic, caused by exogenous insulin or insulin secretagogues. This classification aligns with the broader endocrine framework of primary glandular excess/deficiency versus secondary/tertiary axis disruption.
Clinical Significance
Hypoglycemia is a common and potentially fatal complication of diabetes therapy. Severe hypoglycemia (Level 3) is associated with a 2-fold increased risk of cardiovascular events and a 3-fold increased risk of mortality in type 2 diabetes [2]B2b. In neonates, hypoglycemia affects up to 30% of at-risk infants and can cause long-term neurodevelopmental impairment [21]B2b. Insulinomas, though rare (incidence 1-4 per million), are the most common cause of endogenous hyperinsulinemic hypoglycemia in non-diabetic adults and are malignant in 5-10% of cases [6]B3b[14]B3b. Post-bariatric hypoglycemia affects an estimated 10-30% of patients after Roux-en-Y gastric bypass and can be disabling [9]D5[17]B2a.
Pearl: Hypoglycemia is defined by Whipple's triad and classified into three ADA levels (≤3.9, <3.0, and requiring assistance). Etiologic classification into diabetic vs. non-diabetic and fasting vs. postprandial guides the diagnostic workup, with insulinoma being the most common endogenous hyperinsulinemic cause in non-diabetic adults [6]B3b[14]B3b.
Axis Physiology, Pathophysiology and Biochemical Signature
- ▸The counter-regulatory axis (insulin, glucagon, epinephrine, cortisol, GH) maintains glucose homeostasis; failure at any node causes hypoglycemia.
- ▸Paired hormone measurements (glucose, insulin, C-peptide, proinsulin, β-hydroxybutyrate) at the time of hypoglycemia fingerprint the lesion: suppressed BOHB indicates insulin excess, elevated BOHB suggests counter-regulatory failure.
- ▸Insulinoma, exogenous insulin, sulfonylurea overdose, NICTH (IGF-2), type B insulin resistance, adrenal insufficiency, GH deficiency, and post-bariatric hypoglycemia each produce a distinct biochemical pattern.
The counter-regulatory axis maintains plasma glucose within a narrow range through a precisely orchestrated interplay of insulin, glucagon, and the neuroendocrine stress response. When this axis breaks, the resulting biochemical signature, defined by paired hormone measurements, fingerprints the specific lesion, guiding diagnosis and targeted therapy.
Normal Glucose Homeostasis: The Counter-Regulatory Axis
Plasma glucose is the controlled variable in a classic negative-feedback loop. Rising glucose triggers insulin secretion from pancreatic β-cells, which suppresses hepatic glucose output and promotes peripheral glucose uptake. Simultaneously, insulin inhibits glucagon secretion from α-cells, reducing glycogenolysis and gluconeogenesis [64]D5. The incretin hormone glucagon-like peptide-1 (GLP-1), released from intestinal L-cells after a meal, potentiates glucose-stimulated insulin secretion and suppresses glucagon, thereby limiting postprandial glucose excursions [66]D5. When glucose falls below the threshold of approximately 3.9 mmol/L (70 mg/dL), insulin secretion ceases, and the counter-regulatory cascade activates: α-cells release glucagon, the adrenal medulla secretes epinephrine, and the hypothalamic-pituitary-adrenal axis mobilizes cortisol and growth hormone (GH) [64]D5. Glucagon acts rapidly on the liver to increase glucose output via glycogenolysis and gluconeogenesis; epinephrine provides a second wave of hepatic glucose production and limits peripheral glucose utilization. Cortisol and GH exert slower, permissive effects over hours. This redundant system normally prevents hypoglycemia even during prolonged fasting or intense exercise.
Pathophysiology: Nodes of Failure
Hypoglycemia arises when one or more nodes in this feedback loop fail. The mechanisms fall into four broad categories:
Excess insulin or insulin-like activity. The classic example is , a pancreatic β-cell tumor that autonomously secretes insulin, suppressing counter-regulatory hormones and driving hypoglycemia [45]D5. Sulfonylurea overdose and exogenous insulin administration produce identical biochemical patterns. Type B insulin resistance syndrome, caused by autoantibodies to the insulin receptor (AIRAbs), paradoxically presents with severe hypoglycemia in a subset of patients; the antibodies can act as partial agonists, causing insulin-independent glucose uptake [31]A1a. Non-islet cell tumor hypoglycemia (NICTH) results from overproduction of high-molecular-weight IGF-2 (big IGF-2) by mesenchymal or epithelial tumors, which activates the insulin receptor and suppresses GH, insulin, and IGF-1 [63]D5[52]D5. The IGF-2/IGF-1 ratio is typically >10:1.
Deficient counter-regulation. Long-standing type 1 and type 2 diabetes is associated with loss of the glucagon response to hypoglycemia, a defect that worsens with disease duration and contributes to hypoglycemia unawareness [64]D5. Adrenal insufficiency (primary or secondary) eliminates cortisol's permissive role in gluconeogenesis and glycogenolysis; bioinactive ACTH due to POMC mutations can cause isolated glucocorticoid deficiency with hypoglycemia [47]C4. GH deficiency, as in Laron syndrome (GH receptor deficiency), leads to transient juvenile hypoglycemia that resolves with age as insulin sensitivity declines [53]D5. Liver failure impairs gluconeogenesis and glycogen storage, while renal failure reduces insulin clearance and gluconeogenic capacity [48]A1c.
Altered glucose metabolism. Post-bariatric hypoglycemia (PBH), most common after Roux-en-Y gastric bypass, results from rapid nutrient delivery to the distal gut, causing an exaggerated GLP-1 response that triggers excessive insulin secretion and reactive hypoglycemia 1-3 hours after meals [9]D5[29]A1b. Exercise-induced hypoglycemia occurs when hepatic glucose output fails to match muscle glucose uptake, particularly in glycogen-depleted states [62]D5. Critical illness, inborn errors of metabolism (e.g., glycogen storage diseases, ), and alcohol ingestion (which inhibits gluconeogenesis) also disrupt normal glucose homeostasis.
Drug-induced. Insulin and sulfonylureas are the most common causes of iatrogenic hypoglycemia. SGLT2 inhibitors, by inducing glucosuria, lower plasma glucose and can precipitate hypoglycemia when combined with insulin or sulfonylureas [68]D5. Glucagon receptor antagonists, under investigation for type 1 diabetes, block the primary counter-regulatory hormone and may increase hypoglycemia risk [26]A1b. Multikinase inhibitors (e.g., sunitinib) can cause hypoglycemia by improving insulin sensitivity or reducing tumor burden in insulinoma [50]D5.
Biochemical Signature: Paired Hormone Patterns
The diagnostic workup hinges on simultaneous measurement of glucose, insulin, C-peptide, proinsulin, and β-hydroxybutyrate (BOHB) at the time of hypoglycemia. The pattern identifies the lesion:
| Condition | Glucose | Insulin | C-peptide | Proinsulin | BOHB | Other |
|---|---|---|---|---|---|---|
| Insulinoma | Low | High | High | High | Low | Negative sulfonylurea screen [45]D5 |
| Exogenous insulin | Low | High | Low | Low | Low | Detectable exogenous insulin analog |
| Sulfonylurea overdose | Low | High | High | High | Low | Positive sulfonylurea screen |
| NICTH (IGF-2) | Low | Low | Low | Low | Low | High IGF-2/IGF-1 ratio [63]D5 |
| Type B insulin resistance | Low | High (or variable) | High (or variable) | Variable | Low | Positive AIRAbs [31]A1a |
| Adrenal insufficiency | Low | Low | Low | Low | High | Low cortisol, high ACTH (primary) or low ACTH (secondary) [47]C4 |
| GH deficiency | Low | Low | Low | Low | High | Low IGF-1, low GH [53]D5 |
| Post-bariatric hypoglycemia | Low (postprandial) | High | High | High | Low | Exaggerated GLP-1 response [9]D5 |
A suppressed BOHB (<0.6 mmol/L) indicates that insulin (or an insulin-like factor) is driving glucose into tissues and inhibiting ketogenesis. Elevated BOHB suggests counter-regulatory failure or substrate deficiency. The 72-hour supervised fast remains the gold standard for provoking hypoglycemia and obtaining these paired samples [45]D5. Novel diagnostic tools, such as the GLP-1 receptor agonist exenatide, can induce hypoglycemia in insulinoma patients within 4 hours, potentially shortening the diagnostic fast [28]A1b. GLP-1 receptor imaging with 18F-exendin-4 PET/CT localizes insulinomas by targeting the overexpressed GLP-1 receptor on β-cell tumors [30]B3b.
Pearl: The biochemical signature of hypoglycemia, defined by paired insulin, C-peptide, proinsulin, and β-hydroxybutyrate, directly reflects the underlying pathophysiology: suppressed BOHB indicates insulin excess, while elevated BOHB points to counter-regulatory failure or substrate deficiency [45]D5[64]D5.
Epidemiology, Etiology and Risk Factors
- ▸Severe hypoglycemia in type 1 diabetes occurs at ~100-130 episodes per 100 patient-years; in type 2 diabetes, ~10-30 per 100 but with higher absolute burden.
- ▸Risk is 2- to 3-fold higher in older adults, African Americans, and those with CKD.
- ▸Non-diabetic causes (insulinoma, CHI, critical illness, inborn errors) are rare but must be considered when Whipple's triad is documented without diabetes.
The burden of hypoglycemia is bimodal, concentrated at the extremes of age and overwhelmingly driven by iatrogenic causes in diabetes, while rarer etiologies, , congenital hyperinsulinism, critical illness, and inborn errors, dominate the non-diabetic population. Understanding the anchors the pretest probability that shapes the diagnostic workup.
Incidence and Prevalence
The true population incidence of hypoglycemia is difficult to establish because most episodes are self-treated or asymptomatic. Severe hypoglycemia (requiring third-party assistance) in type 1 diabetes occurs at a rate of approximately 100 to 130 episodes per 100 patient-years; in insulin-treated type 2 diabetes, the rate is substantially lower at 10 to 30 episodes per 100 patient-years, though absolute numbers are higher given the larger population [70]A1c. The ACCORD trial reported that 10.5% of intensively treated participants experienced at least one episode of severe hypoglycemia over a mean follow-up of 3.5 years [75]A1b. Among hospitalized patients, hypoglycemia (blood glucose <70 mg/dL) occurs in 5 to 10% of general medicine patients and up to 25% of critically ill patients [78]A1b. For non-diabetic hypoglycemia, the incidence is far lower: insulinoma has an estimated incidence of 1 to 4 cases per 1,000,000 person-years [70]A1c. Congenital hyperinsulinism (CHI) occurs in approximately 1 in 25,000 to 50,000 live births, with higher rates in populations with founder mutations [83]B2b[99]B2b.
Demographic Distribution
Age. Hypoglycemia is most frequent in the very young and the very old. In neonates, the incidence of transient neonatal hypoglycemia (first 48 hours of life) is 5 to 15%, rising to 30 to 50% in at-risk groups such as infants of diabetic mothers, preterm infants, and those with intrauterine growth restriction [93]D5. In older adults (≥65 years), the risk of severe hypoglycemia increases 2- to 3-fold compared with middle-aged adults, driven by polypharmacy, renal impairment, and impaired counterregulatory responses [85]D5. In the DPV registry (31,330 young patients with type 1 diabetes, median age 12.7 years), admission for severe hypoglycemia occurred at a rate of 2.3 per 100 patient-years in children aged <6 years, declining to 1.5 per 100 patient-years in adolescents [89]B2b.
Sex. The risk of hypoglycemia is similar in males and females with type 1 diabetes; however, in type 2 diabetes, some studies report a modestly increased risk in women, potentially due to lower body weight and higher insulin sensitivity [72]A1b. Insulinoma shows a female predominance (female-to-male ratio approximately 1.5:1) [70]A1c.
Geography and Ethnicity. The prevalence of severe hypoglycemia varies significantly by geography, reflecting differences in diabetes prevalence, healthcare access, and therapeutic regimens. In the United States, hospitalization rates for hypoglycemia among older adults with diabetes are 2- to 3-fold higher in African Americans and Hispanics compared with non-Hispanic whites, even after adjusting for glycemic control [48]A1c. The ACCORD study found that black participants had a hazard ratio (HR) of 1.67 (95% CI 1.28-2.17) for severe hypoglycemia compared with white participants [75]A1b. In Asia, the incidence of severe hypoglycemia among insulin-treated patients is generally higher than in Western populations, partly due to lower body mass index and differences in dietary patterns [82]B2b.
Temporal Trends
The incidence of severe hypoglycemia has declined over the past two decades in many settings, largely attributable to the introduction of safer insulin analogs, wider use of continuous glucose monitoring (CGM) and automated insulin delivery (AID) systems, and revised glycemic targets [95]A1c. In type 1 diabetes, rates of severe hypoglycemia have fallen from approximately 30 to 60 episodes per 100 patient-years in the 1990s to less than 10 episodes per 100 patient-years in contemporary cohorts using AID [71]A1b[95]A1c. However, in older adults and those with renal impairment, rates remain stubbornly high, partly because of inconsistent access to technology and ongoing therapeutic inertia [94]B2a.
Etiology: Mechanistic Categories
Hypoglycemia is classified by the Endocrine Society into two broad categories: diabetic (overwhelmingly iatrogenic) and non-diabetic (further subdivided into insulin-mediated and non-insulin-mediated) [70]A1c.
Iatrogenic (Diabetic). Accounts for >95% of all clinically significant hypoglycemia. Predisposing factors include: missed meals, excessive insulin or sulfonylurea dosing, unanticipated exercise, alcohol ingestion, renal impairment, and the use of beta-blockers masking warning symptoms [70]A1c[89]B2b. The GRADE trial (Glycemia Reduction Approaches in Diabetes) showed that the arm had the highest rate of hypoglycemia (severe hypoglycemia incidence 2.3 per 100 patient-years) compared with (0.6) or sitagliptin (0.1) in -treated type 2 diabetes [36]A1b.
Insulinoma. A pancreatic neuroendocrine tumor causing autonomous insulin secretion. Nearly all cases are sporadic; approximately 5-10% are associated with multiple endocrine neoplasia type 1 (MEN1) [70]A1c.
Congenital Hyperinsulinism (CHI). Caused by mutations in genes regulating insulin secretion (ABCC8, KCNJ11, GLUD1, GCK, HADH, SLC16A1). In a Norwegian nationwide cohort, 77 of 98 probands (79%) had confirmed CHI; genetic cause was identified in 72% of these, with ABCC8 mutations accounting for the majority [83]B2b. In an Iranian cohort, the most common mutation was in ABCC8 (45.5%), followed by KCNJ11 (15.2%) [99]B2b.
Critical Illness. Hypoglycemia in the ICU is associated with increased mortality (adjusted OR 1.6 to 2.8 in most studies) [78]A1b. Tight glycemic control protocols (target 80-110 mg/dL) increase hypoglycemia risk approximately 3-fold compared with liberal targets [78]A1b.
Other Non-diabetic Causes. These include: reactive hypoglycemia (post-gastric bypass), , autoimmune hypoglycemia (insulin autoimmune syndrome, anti-insulin receptor antibodies), non-islet cell tumor hypoglycemia (NICTH, mediated by IGF-2 overproduction), adrenal insufficiency (including pseudo-neonatal adrenoleukodystrophy due to biallelic ACOX1 mutations) [84]C4, and inborn errors of metabolism (glycogen storage diseases, ) [70]A1c.
Risk Factors
Table 1 summarizes the major risk factors for hypoglycemia with their associated odds ratios or relative risks.
Seasonal Variation
Seasonal variation in hypoglycemia is reported predominantly in type 1 diabetes, with higher rates during summer months, likely due to increased physical activity, altered eating patterns, and increased insulin sensitivity with higher ambient temperatures [89]B2b. The difference is modest, approximately 15-20% relative increase in summer versus winter, but may be amplified in young children [89]B2b. In contrast, severe hypoglycemia in type 2 diabetes shows minimal seasonal variation.
Special Populations
Neonates. Transient neonatal hypoglycemia is most common in infants of diabetic mothers (gestational or pre-existing diabetes). Risk factors include maternal hyperglycemia during labor, prematurity (<37 weeks), intrauterine growth restriction, and perinatal stress (e.g., asphyxia, hypothermia) [93]D5[19]A1a.
Pregnancy. Hypoglycemia is a frequent complication of pregnancy in women with pre-existing type 1 diabetes, occurring in up to 40-50% of pregnancies, with the highest risk in the first trimester due to nausea, vomiting, and insulin sensitivity fluctuations [73]B2b. The TOBOGM study demonstrated that early-pregnancy glycemia is continuously associated with adverse outcomes [73]B2b.
Post-bariatric Surgery. Roux-en-Y gastric bypass increases the risk of late dumping syndrome and reactive hypoglycemia, occurring in 5-10% of patients, typically 1-3 hours postprandially. The risk is mediated by rapid gastric emptying and exaggerated GLP-1 secretion [70]A1c.
Chronic Kidney Disease (CKD). The risk of severe hypoglycemia is increased 2- to 4-fold in patients with CKD stage 3-5 compared with those with preserved renal function, due to decreased clearance of insulin and oral hypoglycemic agents (particularly sulfonylureas) and impaired gluconeogenesis [48]A1c[85]D5.
Critical Illness. Sepsis, hepatic failure, and renal failure all predispose to hypoglycemia via impaired gluconeogenesis, increased glucose utilization, and altered drug clearance [78]A1b.
Pearl: More than 95% of clinically significant hypoglycemia is iatrogenic in patients with diabetes; therefore, a thorough medication history (timing, dose, missed meals, exercise, alcohol) is the single most important element of the initial evaluation. In non-diabetic patients, a low index of suspicion for insulinoma, CHI, or critical illness is essential, as these conditions are rare but treatable.
| Factor | Odds Ratio / Relative Risk | Evidence Level |
|---|---|---|
| Insulin therapy (T1DM vs T2DM) | 5-10x relative risk | 1b [70]A1c |
| Intensive glycemic control (HbA1c <6.0%) in T2DM (ACCORD) | HR 2.8 (95% CI 2.1-3.7) | 1b [75]A1b |
| Age ≥65 years | RR 2.0-3.0 | 2b [85]D5 |
| CKD stage 3-5 | RR 2.0-4.0 | 2b [48]A1c |
| African American ethnicity | HR 1.67 (95% CI 1.28-2.17) | 1b [75]A1b |
| Sulfonylurea vs metformin (T2DM) | RR 2.5 (95% CI 1.8-3.5) | 1b [77]A1b |
| Congenital hyperinsulinism (ABCC8 mutation) | ~1/25,000-50,000 live births | 2b [83]B2b |
| Pregnancy (T1DM, first trimester) | RR 1.5-2.0 | 2b [73]B2b |
| Post-bariatric surgery (reactive) | RR 5-10% prevalence | 2b [70]A1c |
| Critical illness (ICU, tight glucose control) | RR 3.0 (95% CI 2.0-4.5) | 1b [78]A1b |
Clinical Presentation
- ▸Hypoglycemia presents with a predictable sequence: autonomic symptoms (tremor, palpitations, diaphoresis) followed by neuroglycopenic symptoms (confusion, slurred speech, weakness) as glucose falls below 2.8 mmol/L (50 mg/dL).
- ▸Focal neurological deficits (hemiparesis, aphasia) can mimic stroke and resolve with glucose administration; always check a bedside glucose in any patient with altered mental status.
- ▸Phenotypic variants (insulinoma, congenital hyperinsulinism, type B insulin resistance, insulin autoimmune syndrome) have distinguishing features that guide diagnosis and management.
The clinical presentation of hypoglycemia is a spectrum defined by the brain's dependence on glucose and the counterregulatory response. Symptoms progress along a predictable timeline: autonomic (adrenergic) symptoms appear first as glucose falls below ~3.9 mmol/L (70 mg/dL), followed by neuroglycopenic symptoms as levels drop below ~2.8 mmol/L (50 mg/dL) [100]A1b. The rate of decline matters, a rapid fall triggers robust autonomic symptoms, while a gradual descent may blunt warning signs, leading to unrecognized neuroglycopenia [110]B3b.
Presenting Symptoms
Patients typically report a sequence of autonomic symptoms: tremor, palpitations, anxiety, diaphoresis, and hunger. These arise from sympathetic activation and epinephrine release [100]A1b. As glucose falls further, neuroglycopenic symptoms emerge: confusion, difficulty concentrating, slurred speech, visual disturbances (blurred vision, diplopia), weakness, and drowsiness [110]B3b. In severe hypoglycemia (glucose < 2.2 mmol/L (40 mg/dL)), seizures, loss of consciousness, and coma can occur [100]A1b. The onset is often acute, over minutes to hours, but in or post-bariatric hypoglycemia, symptoms may be more gradual and postprandial [107]B3b.
Neurological Examination Findings
The neurological examination in hypoglycemia is dynamic and correlates with glucose level. Early findings include tachycardia, , and diaphoresis. As neuroglycopenia progresses, the examiner may detect:
- Mental status: Confusion, disorientation, agitation, or lethargy. The patient may appear intoxicated.
- Motor: Focal or generalized weakness, ataxia, or tremor. Seizures (generalized tonic-clonic) occur in 10-20% of severe episodes [100]A1b.
- Sensory: Paresthesias or numbness, though less common.
- Reflexes: Hyperreflexia and extensor plantar responses (Babinski sign) can be present transiently.
- Cranial nerves: Slurred speech (dysarthria), diplopia, or blurred vision. Pupils may be dilated.
- Autonomic: Profuse sweating, pallor, and piloerection.
A key examination maneuver is to assess for focal neurological deficits that mimic stroke, hypoglycemia can cause hemiparesis, aphasia, or hemisensory loss, which resolve with glucose administration [110]B3b. The examiner should also check for (suggesting insulin resistance, as in type B insulin resistance syndrome) and hepatomegaly (glycogen storage disease or lymphoma) [103]C4[108]C4.
Phenotypic Variants
Hypoglycemia presents differently depending on etiology. The table below summarizes key variants:
| Variant | Key Features | Frequency |
|---|---|---|
| Diabetic (iatrogenic) | Autonomic symptoms prominent; often related to insulin or sulfonylurea dosing; may be nocturnal or exercise-induced [100]A1b | Most common cause in adults |
| Insulinoma | Whipple's triad: symptoms with fasting, low glucose, relief with glucose; often gradual onset; weight gain [107]B3b | Rare (~1-4 per million) |
| Congenital hyperinsulinism (CHI) | Neonatal or infancy onset; severe, persistent hypoglycemia; may be diazoxide-responsive or -unresponsive [104]C4[114]C4 | ~1 in 50,000 births |
| Type B insulin resistance | Alternating hyperglycemia and hypoglycemia; acanthosis nigricans; autoimmune features [108]C4[119]C4 | Very rare |
| Insulin autoimmune syndrome (Hirata disease) | Postprandial hypoglycemia; high insulin and C-peptide; anti-insulin antibodies [122]C4 | Rare, more common in Asian populations |
| Non-islet cell tumor hypoglycemia (NICTH) | Severe fasting hypoglycemia; large mesenchymal tumors; low insulin, low IGF-1, high IGF-2 [103]C4 | Rare |
| Adrenal insufficiency | Hypoglycemia with hypotension, hyperpigmentation, fatigue; often in stress [102]C4 | Uncommon |
| Post-bariatric surgery | Early dumping or late postprandial hypoglycemia; occurs 1-3 hours after meals [107]B3b | Increasingly recognized |
Red Flags
Certain symptoms require urgent action:
- Respiratory compromise: Tachypnea, Kussmaul breathing (if from Warburg effect) [103]C4.
- Autonomic instability: Severe bradycardia or hypotension (adrenal crisis) [102]C4.
- Seizures or coma: Immediate glucose administration needed.
- Focal neurological deficits: Mimics stroke; give glucose before imaging.
- Persistent hypoglycemia despite dextrose: Consider insulinoma, sulfonylurea overdose, or insulin autoimmune syndrome.
FVC < 15 mL/kg or oxygen saturation < 90% in a patient with hypoglycemia and respiratory distress should prompt consideration of intubation and mechanical ventilation, especially in the setting of lactic acidosis or sepsis [103]C4.
Atypical Presentations
Hypoglycemia can present in ways that delay diagnosis:
- Asymptomatic hypoglycemia: Common in patients with type 1 diabetes and hypoglycemia unawareness, or in neonates [110]B3b. The Warburg effect can cause profound hypoglycemia (glucose 1.4 mmol/L) without neuroglycopenia due to brain adaptation to lactate as fuel [103]C4.
- Nocturnal hypoglycemia: Presents with morning headache, fatigue, night sweats, or nightmares. Often unrecognized [100]A1b.
- Hypoglycemia in pregnancy: May present with nausea, vomiting, and altered mental status; can be mistaken for hyperemesis or preeclampsia [106]B2b.
- Hypoglycemia in critical illness: Sepsis, liver failure, or renal failure can cause hypoglycemia without typical autonomic symptoms [100]A1b.
- Factitious hypoglycemia: Surreptitious insulin or sulfonylurea use; may present with severe, recurrent episodes and normal C-peptide (if exogenous insulin) or elevated C-peptide (if sulfonylurea) [100]A1b.
Pearl: Hypoglycemia can mimic stroke, intoxication, or seizure disorder; always check a bedside glucose in any patient with altered mental status or focal neurological deficits, as prompt correction can reverse symptoms and prevent permanent brain injury [100]A1b[110]B3b.
Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization
- ▸Whipple's triad is the essential diagnostic gatekeeper; without it, further workup is not indicated.
- ▸A critical sample at the time of hypoglycemia (glucose <55 mg/dL) with paired insulin, C-peptide, proinsulin, and beta-hydroxybutyrate distinguishes endogenous hyperinsulinism from other causes.
- ▸The supervised 72-hour fast has ~95% sensitivity for insulinoma; localization requires triple-phase CT, EUS, GLP-1 receptor PET/CT, or selective arterial calcium stimulation with hepatic venous sampling.
The diagnosis of hypoglycemia begins with Whipple's triad: (1) symptoms or signs consistent with hypoglycemia, (2) a low plasma glucose concentration at the time of symptoms, and (3) resolution of symptoms after glucose administration [70]A1c. This triad is the diagnostic gatekeeper, without it, further workup is not indicated. Once Whipple's triad is documented, the next step is to determine the biochemical mechanism driving the low glucose.
Biochemical Confirmation: Paired Hormones
At the moment of hypoglycemia (plasma glucose <55 mg/dL [3.0 mmol/L]), draw a critical sample that includes glucose, insulin, C-peptide, proinsulin, beta-hydroxybutyrate (BOHB), and a screen for sulfonylureas/meglitinides [70]A1c[148]B3b. The pattern of these results distinguishes endogenous hyperinsulinism from other causes.
| Parameter | Endogenous Hyperinsulinism | Non-Insulin-Mediated Hypoglycemia |
|---|---|---|
| Insulin | ≥3 μIU/mL (≥18 pmol/L) | <3 μIU/mL |
| C-peptide | ≥0.6 ng/mL (≥0.2 nmol/L) | <0.6 ng/mL |
| Proinsulin | ≥5 pmol/L | <5 pmol/L |
| Beta-hydroxybutyrate | ≤2.7 mmol/L | >2.7 mmol/L |
| Sulfonylurea screen | Negative | Negative (or positive if surreptitious use) |
A suppressed BOHB (<2.7 mmol/L) is a hallmark of insulin-mediated hypoglycemia because insulin inhibits ketogenesis [70]A1c. Conversely, elevated BOHB suggests alternative causes such as or . C-peptide is critical to differentiate endogenous insulin secretion (elevated) from exogenous insulin administration (suppressed). Proinsulin is often disproportionately elevated in due to defective processing [45]D5.
Dynamic Testing: The 72-Hour Fast
When spontaneous hypoglycemia is not captured, the supervised 72-hour fast is the gold-standard provocation test for fasting hypoglycemia [70]A1c[148]B3b. The fast is performed in a controlled inpatient setting. Plasma glucose is measured every 4 to 6 hours; when glucose falls below 60 mg/dL (3.3 mmol/L), measurements become hourly. The fast is terminated when:
- Plasma glucose <45 mg/dL (2.5 mmol/L) with symptoms, OR
- Plasma glucose <50 mg/dL (2.8 mmol/L) without symptoms after 72 hours, OR
- The patient develops neuroglycopenic symptoms.
At termination, draw the critical sample (glucose, insulin, C-peptide, proinsulin, BOHB, sulfonylurea screen). The diagnostic cutoffs are the same as above. The 72-hour fast has a sensitivity of approximately 95% for insulinoma [45]D5. In a cohort of 159 patients, a C-peptide cutoff of ≥0.6 ng/mL at the time of hypoglycemia had a sensitivity of 92% and specificity of 97% for endogenous hyperinsulinism [148]B3b.
Mixed-Meal Test for Reactive Hypoglycemia
For patients with symptoms occurring 2 to 4 hours after meals (postprandial hypoglycemia), a 5-hour mixed-meal test is preferred over the 72-hour fast [70]A1c. The patient consumes a standardized mixed meal (not pure glucose, which can cause ). Glucose, insulin, and C-peptide are measured every 30 minutes. A positive test requires reproduction of symptoms with a plasma glucose <55 mg/dL (3.0 mmol/L) and concomitant elevated insulin/C-peptide. This pattern is seen in and early .
Localization of Insulinoma
Once biochemical diagnosis of endogenous hyperinsulinism is established, localization is mandatory. Triple-phase CT (pancreatic protocol) detects 70-80% of insulinomas [45]D5. Endoscopic ultrasound (EUS) with fine-needle aspiration has sensitivity of 80-90% for pancreatic /body lesions [45]D5. GLP-1 receptor PET/CT using 68Ga-exendin-4 or 18F-exendin-4 is emerging as a highly sensitive modality, detecting insulinomas in 95% of cases in a phase 2 trial [30]B3b. For occult tumors, selective arterial calcium stimulation with hepatic venous sampling (SACST) remains the gold standard: calcium injection into the gastroduodenal, splenic, or superior mesenteric artery causes a >2-fold rise in hepatic vein insulin within 30-60 seconds, localizing the tumor to the corresponding pancreatic region [45]D5.
Other Diagnostic Considerations
- Non-islet cell tumor hypoglycemia (NICTH): Suspect when insulin and C-peptide are suppressed. Measure IGF-II (total and high-molecular-weight "big" IGF-II). A ratio of big IGF-II to total IGF-II >0.2 is diagnostic [142]C4[161]D5.
- Adrenal insufficiency: Morning cortisol <3 μg/dL (83 nmol/L) or a poor response to cosyntropin (250 μg) confirms [84]C4.
- Congenital hyperinsulinism in infants: Genetic testing for ABCC8, KCNJ11, GCK, GLUD1, HNF4A, HADH is indicated [99]B2b[147]B3b[149]C4. 18F-DOPA PET/CT distinguishes focal from diffuse disease [143]C4.
- Factitious hypoglycemia: Screen for sulfonylureas and insulin antibodies. Exogenous insulin suppresses C-peptide; sulfonylureas elevate both insulin and C-peptide [70]A1c.
Diagnostic Algorithm
Step 1: Document Whipple's triad (symptoms + low glucose + relief with glucose). Step 2: Obtain critical sample at time of hypoglycemia (glucose, insulin, C-peptide, proinsulin, BOHB, sulfonylurea screen). Step 3: If critical sample shows endogenous hyperinsulinism (insulin ≥3, C-peptide ≥0.6, proinsulin ≥5, BOHB ≤2.7), proceed to localization. Step 4: If critical sample is non-diagnostic and fasting hypoglycemia suspected, perform supervised 72-hour fast. Step 5: If postprandial pattern, perform 5-hour mixed-meal test. Step 6: Localize with triple-phase CT or EUS as first line; if negative, proceed to GLP-1 receptor PET/CT or SACST. Step 7: If insulin/C-peptide suppressed, evaluate for NICTH (IGF-II), adrenal insufficiency (cortisol), or inborn errors of metabolism.
Pearl: The 72-hour fast remains the gold standard for diagnosing fasting hypoglycemia, but a properly timed critical sample during spontaneous hypoglycemia can obviate the need for provocation in up to 40% of cases [70]A1c[148]B3b.
Severity, Staging and Risk Stratification
- ▸Hypoglycemia severity is classified into three levels by ADA/Endocrine Society: Level 1 (<70 mg/dL), Level 2 (<54 mg/dL), and Level 3 (requiring assistance) [171,172].
- ▸CGM-derived time below range (TBR) <54 mg/dL is a strong independent predictor of future severe hypoglycemia; each 1% increase in TBR2 raises risk by 15% [164].
- ▸Insulinoma staging in MEN1 requires consideration of multifocality and recurrence risk; distal pancreatectomy offers better recurrence-free survival than enucleation [6].
Hypoglycemia severity is stratified into three levels by the American Diabetes Association and the Endocrine Society [171]A1c[172]A1c. Level 1 is a glucose alert value of <70 mg/dL (3.9 mmol/L) but ≥54 mg/dL (3.0 mmol/L). Level 2 is clinically significant hypoglycemia at <54 mg/dL (3.0 mmol/L). Level 3 is severe hypoglycemia characterized by cognitive impairment requiring external assistance for recovery, regardless of the measured glucose level [171]A1c[172]A1c. This classification directly determines treatment intensity: Level 1 prompts immediate carbohydrate intake (15-20 g), Level 2 requires urgent intervention (often with glucagon if oral intake is unsafe), and Level 3 mandates parenteral therapy (glucagon or intravenous dextrose) [123]A1c[171]A1c.
Risk Stratification for Recurrent Hypoglycemia
Identifying patients at high risk for recurrent severe hypoglycemia is essential for selecting surveillance intervals and preventive strategies. The strongest predictors include a prior episode of Level 3 hypoglycemia, hypoglycemia unawareness, impaired counterregulatory hormone responses, and use of insulin or sulfonylureas [123]A1c[165]A1a. Continuous glucose monitoring (CGM) provides quantitative risk stratification: baseline time below range (TBR) <70 mg/dL (TBR1) and <54 mg/dL (TBR2) independently predict future severe hypoglycemia in type 1 diabetes [164]B2b. In a pooled analysis of six clinical trials (n=1,433), each 1% increase in TBR2 was associated with a 15% higher relative risk of severe hypoglycemia (HR 1.15, 95% CI 1.08-1.23) [164]B2b. The Endocrine Society recommends CGM for all individuals with diabetes at high risk for hypoglycemia, particularly those with a history of Level 3 events or hypoglycemia unawareness [123]A1c[162]A1c.
Staging of Insulinomas and Surgical Urgency
For insulinomas, staging integrates tumor size, location, and genetic context to determine surgical urgency. Sporadic insulinomas are typically small (<2 cm) and benign; surgical enucleation or achieves cure in >90% of cases [70]A1c. In multiple endocrine neoplasia type 1 (MEN1), insulinomas are often multifocal and recur after surgery. A retrospective GTE study of 73 MEN1 patients found that recurrence-free survival at 10 years was 62% after enucleation versus 85% after distal pancreatectomy (HR 2.4, 95% CI 1.1-5.2) [6]B3b. Surgical urgency is driven by the severity of hypoglycemia: patients with Level 2 or Level 3 events despite medical therapy (diazoxide, somatostatin analogs) require expedited resection [70]A1c[125]D5. Malignant insulinomas (10% of cases) are staged by the presence of metastases; surgical debulking or liver-directed therapy is considered for symptom control [70]A1c.
Risk Stratification in Special Populations
Neonates: Transitional hypoglycemia (glucose nadir 57 mg/dL at 2-4 hours of life) is physiologic, but persistent hypoglycemia beyond 48 hours requires evaluation for hyperinsulinism [170]D5. The risk of neurologic injury is highest with glucose <40 mg/dL for >1 hour; diazoxide is first-line therapy for confirmed hyperinsulinism [125]D5[170]D5. Post-bariatric surgery: Post-bariatric hypoglycemia (PBH) is classified by severity: mild (self-treated, <1 episode/week), moderate (requires assistance, 1-3 episodes/week), and severe (≥1 Level 3 episode/month) [17]B2a. Prevalence of severe PBH is 0.1-2% after Roux-en-Y gastric bypass [17]B2a. Chronic kidney disease (CKD): Reduced renal clearance of insulin and sulfonylureas increases hypoglycemia risk. Use of glucose-containing dialysate (100-200 mg/dL) during hemodialysis reduces intradialytic hypoglycemia by 40% (RR 0.60, 95% CI 0.45-0.80) compared with glucose-free dialysate [178]A1a. Critical illness: Tight glycemic control (target 80-110 mg/dL) in critically ill children increased severe hypoglycemia (<40 mg/dL) from 2% to 7% (RR 3.5, 95% CI 1.8-6.8) without mortality benefit [168]A1b. In adults with combined DKA and hyperosmolar hyperglycemic state, the risk of hypoglycemia during treatment is 25% higher than in isolated DKA (OR 1.25, 95% CI 1.02-1.53) [169]B2b. Long-term care: The ADA recommends individualized glycemic goals based on comorbidity burden; for frail older adults, a less stringent target (HbA1c <8.5%) is advised to minimize hypoglycemia risk [1]A1c.
Tools for Risk Prediction
CGM-derived metrics beyond TBR include time in range (TIR, 70-180 mg/dL) and glycemic variability (coefficient of variation). A TIR <50% combined with TBR2 >5% identifies patients with a 3-fold increased risk of Level 3 hypoglycemia over 6 months [165]A1a. The Hypoglycemia Risk Score (HRS), incorporating age, renal function, insulin use, and prior events, has moderate discrimination (C-statistic 0.72) in type 2 diabetes [165]A1a.
Pearl: Hypoglycemia severity classification (Level 1-3) guides immediate treatment, while CGM-derived TBR metrics and clinical risk factors (prior severe events, unawareness, CKD) stratify long-term risk and determine surveillance intensity and preventive therapy [123]A1c[164]B2b[171]A1c.
| Level | Glucose Threshold | Clinical Description | Recommended Action |
|---|---|---|---|
| 1 | <70 mg/dL (3.9 mmol/L) but ≥54 mg/dL (3.0 mmol/L) | Alert value; may be asymptomatic | Oral carbohydrate 15-20 g; recheck in 15 min [171]A1c |
| 2 | <54 mg/dL (3.0 mmol/L) | Clinically significant; neuroglycopenic symptoms likely | Urgent oral or parenteral glucose; consider glucagon if unable to take orally [171]A1c |
| 3 | No specific glucose threshold | Cognitive impairment requiring external assistance | Parenteral glucagon or IV dextrose; emergency medical services [171]A1c |
| Risk Factor | Relative Risk (95% CI) | Source |
|---|---|---|
| Prior Level 3 hypoglycemia | OR 3.2 (2.1-4.8) | [123]A1c |
| Hypoglycemia unawareness | OR 2.8 (1.9-4.1) | [123]A1c |
| TBR2 >5% (CGM) | HR 1.15 per 1% increase (1.08-1.23) | [164]B2b |
| CKD (eGFR <30 mL/min) | OR 2.1 (1.4-3.1) | [165]A1a |
| Insulin or sulfonylurea use | OR 1.8 (1.3-2.5) | [165]A1a |
Acute Management and Endocrine Emergencies
- ▸Acute management follows the Rule of 15 for conscious patients and parenteral glucagon or dextrose for severe hypoglycemia.
- ▸Refractory hypoglycemia, especially from sulfonylurea overdose, requires octreotide and continuous IV dextrose infusion.
- ▸ICU glucose targets should be 140-180 mg/dL to avoid harm from tight control (NICE-SUGAR).
Step 1: Initial Assessment and Severity Classification
Classify hypoglycemia severity immediately upon presentation. Mild hypoglycemia (glucose 54-69 mg/dL [3.0-3.9 mmol/L]) allows self-treatment with oral . Moderate hypoglycemia (glucose <54 mg/dL [3.0 mmol/L]) often requires assistance but the patient can still swallow. Severe hypoglycemia (glucose <54 mg/dL with altered mental status, seizure, or unconsciousness) demands parenteral therapy and urgent medical attention [123]A1c. The Endocrine Society 2023 guideline defines a glucose threshold of <54 mg/dL as clinically important hypoglycemia because it correlates with cognitive impairment and autonomic activation [123]A1c. Disposition depends on severity: mild cases can be managed at home with education; moderate cases may require emergency department evaluation; severe cases warrant hospital admission, often to an intensive care unit for monitoring and prevention of recurrence.
Step 2: First-Line Intervention, The Rule of 15
For conscious patients able to swallow, administer 15-20 g of oral glucose (e.g., 3-4 glucose tablets, 4-6 oz juice, or 1 tablespoon sugar). Recheck capillary glucose in 15 minutes. If glucose remains <70 mg/dL (3.9 mmol/L), repeat the same dose. This “Rule of 15” is the cornerstone of acute [123]A1c. For unconscious patients or those unable to take oral, give glucagon 1 mg intramuscularly (IM), subcutaneously (SC), or intravenously (IV). Onset is 5-15 minutes; the dose is 0.5 mg for children <25 kg or <5 years [123]A1c. Alternatively, administer IV dextrose 50% (D50) 25 g (50 mL) in adults or 0.5-1 g/kg as D25 (2 mL/kg) in children [123]A1c. IV dextrose acts within 1-3 minutes but carries a risk of extravasation and hyperglycemia. Glucagon is preferred in out-of-hospital settings because it does not require IV access.
Step 3: Second-Line and Refractory Hypoglycemia
If glucose remains <70 mg/dL after two doses of dextrose or glucagon, initiate a continuous IV dextrose infusion (e.g., D10 at 50-100 mL/h) titrated to maintain glucose 100-150 mg/dL [123]A1c. For suspected sulfonylurea overdose, a common cause of refractory hypoglycemia, administer octreotide 50-100 mcg SC or IV every 6-12 hours to suppress endogenous insulin secretion [123]A1c. Octreotide is a somatostatin analogue that blocks calcium-dependent insulin release and can prevent recurrent hypoglycemia for 6-12 hours per dose. In , acute management is similar, but definitive therapy (surgery or diazoxide) is pursued after stabilization. For factitious hypoglycemia (insulin or sulfonylurea abuse), treat with dextrose and arrange psychiatric evaluation.
Step 4: Monitoring and Titration
After initial correction, measure glucose every 15-30 minutes until stable >70 mg/dL, then every 1-2 hours for 4-6 hours to detect recurrence [123]A1c. In hospitalized patients, continuous glucose monitoring (CGM) reduces the time spent in hypoglycemia compared with point-of-care testing alone [131]A1b [182]B2a. The TIGHT trial (2025) showed that CGM-guided intensive therapy (target 90-130 mg/dL) increased time in range without increasing severe hypoglycemia in non-ICU patients [131]A1b. However, CGM must be calibrated and interpreted with caution in critically ill patients due to potential lag and interference [182]B2a. For patients on insulin or sulfonylureas, identify the precipitating cause (missed meal, excessive dose, illness) and adjust the regimen accordingly.
Step 5: Resolution and Transition
Once glucose is stable >70 mg/dL for 4-6 hours, transition to oral carbohydrates and resume the patient’s usual diabetes medications with appropriate dose reductions. For severe hypoglycemia requiring hospitalization, consult endocrinology to optimize the long-term regimen. Provide education on hypoglycemia prevention: sick-day rules, medication adjustment, and glucagon kit use. The Endocrine Society recommends that all patients at risk for severe hypoglycemia (those on insulin or sulfonylureas) have a glucagon prescription and a written action plan [123]A1c.
Drug Dosing Table
| Drug | Route | Dose (Adults) | Dose (Children) | Onset | Duration | Key Monitoring |
|---|---|---|---|---|---|---|
| Oral glucose | PO | 15-20 g | 0.3 g/kg | 5-10 min | 30-60 min | Recheck glucose in 15 min |
| Glucagon | IM/SC/IV | 1 mg | 0.5 mg (<25 kg or <5 y) | 5-15 min | 30-60 min | Nausea, vomiting; ensure airway |
| Dextrose 50% | IV | 25 g (50 mL) | 0.5-1 g/kg (D25 2 mL/kg) | 1-3 min | 30-60 min | Extravasation risk; hyperglycemia |
| Octreotide | SC/IV | 50-100 mcg q6-12h | Not established | 30 min | 6-12 h | For sulfonylurea overdose; monitor glucose |
Treatment Failure Protocol
If glucose remains <70 mg/dL after two doses of dextrose/glucagon, start IV dextrose infusion (D10 at 50-100 mL/h) and titrate to glucose 100-150 mg/dL. Consider octreotide if sulfonylurea overdose is suspected. If refractory, evaluate for insulinoma, non-islet cell tumor hypoglycemia, or adrenal insufficiency. Consult endocrinology.
What NOT to Do
- Do not use insulin to treat hypoglycemia.
- Do not administer long-acting insulin to prevent rebound hyperglycemia; instead, use short-acting insulin cautiously after glucose stabilizes.
- Do not discharge a patient with severe hypoglycemia without identifying the cause and providing a prevention plan.
- Do not use bicarbonate for hypoglycemia, no evidence supports this practice.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication for practice |
|---|---|---|---|---|
| Glucose target in ICU | NICE-SUGAR (2009): target 81-108 mg/dL increased mortality vs <180 mg/dL (HR 1.14, 95% CI 1.02-1.28) [183]A1b | Leuven trials: tight control reduced mortality in surgical ICU | Strong (RCTs with conflicting results) [183]A1b | Current guidelines recommend target 140-180 mg/dL in ICU [85]D5; avoid tight targets due to hypoglycemia risk |
| Use of CGM in hospital | ADA 2025 supports CGM for non-ICU patients with appropriate protocols [131]A1b | Endocrine Society 2025 notes lack of standardized implementation [182]B2a | Moderate (evidence base growing but protocols lacking) | CGM can reduce hypoglycemia but requires validation in critically ill; use with caution |
| SGLT2 inhibitors in type 1 diabetes | EASE trials show reduced HbA1c and weight but increased risk of euglycemic DKA (OR 3.2, 95% CI 1.5-6.8) [180]A1b | FDA warning (2015) highlights ketoacidosis risk [186]D5 | Strong (label restricts use to type 2 diabetes; off-label in type 1) | Avoid SGLT2 inhibitors in type 1 diabetes unless in clinical trial; monitor ketones if used |
Pearl: For acute hypoglycemia, the Rule of 15 (15g oral glucose, recheck in 15 min) is first-line in conscious patients; for severe hypoglycemia with altered mental status, administer IM glucagon 1 mg or IV dextrose 25g immediately, and if refractory, consider octreotide for sulfonylurea overdose and continuous dextrose infusion [123]A1c.
Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive)
- ▸Long-term management requires a treat-to-target strategy with an etiology-specific biochemical endpoint (fasting glucose >70 mg/dL for insulinoma/CHI/PBH; HbA1c <7% with time below range <4% for diabetes).
- ▸Diazoxide (3-8 mg/kg/day) is first-line for insulinoma and CHI; avexitide (30 mg SC BID) is effective for refractory post-bariatric hypoglycemia (PREVENT trial).
- ▸Definitive surgical cure (enucleation or pancreatectomy) achieves >90% cure for benign insulinoma and focal CHI; avoid intensive glycemic targets (target 140-180 mg/dL) in critically ill patients (NICE-SUGAR, NNT=11 for excess death).
The choice among hormone replacement, hormone suppression, and definitive surgical cure depends entirely on the underlying etiology, but the overarching principle is a treat-to-target strategy anchored to a specific biochemical goal. For hypoglycemia due to hormone deficiency (e.g., cortisol or growth hormone), the target is physiologic replacement. For hyperinsulinemic hypoglycemia from or post-bariatric surgery, the target is suppression of excessive insulin secretion. For insulin-dependent diabetes, the target is glycemic stability within a defined range that minimizes both hyperglycemia and iatrogenic hypoglycemia. Each pathway requires a defined biochemical endpoint, a titration strategy, and a monitoring schedule to verify that the target is reached and maintained without overshooting into recurrent hypoglycemia.
Step 1: Establish the Biochemical Target
Before any long-term therapy begins, document the patient's baseline profile with a paired fasting or postprandial glucose, insulin, C-peptide, and, when indicated, cortisol, GH, or IGF-1. The biochemical target is etiology-specific:
- Insulinoma (preoperative medical ): Achieve fasting glucose >70 mg/dL (3.9 mmol/L) and suppress insulin secretion sufficiently to prevent symptoms. The Endocrine Society 2009 guideline recommends diazoxide 3-8 mg/kg/day orally in two to three divided doses as first-line medical therapy for insulinoma (strong recommendation, moderate-quality evidence) [70]A1c. Diazoxide opens ATP-sensitive potassium channels on beta cells, directly inhibiting insulin release.
- Post-bariatric hypoglycemia (PBH): Target postprandial glucose nadir >70 mg/dL. The PREVENT trial (N=18) showed that avexitide (exendin-9,39) 30 mg subcutaneously twice daily raised glucose nadir from 55 to 68 mg/dL during mixed-meal tolerance testing (P<0.001) and reduced hypoglycemia event rate by 67% [196]A1b. The Endocrine Society 2022 guideline recognizes the use of a GLP-1 antagonist as a therapeutic option in refractory PBH (conditional recommendation, low-quality evidence) [124]A1a.
- Congenital hyperinsulinism (CHI): Target fasting glucose >70 mg/dL. First-line medical therapy is diazoxide 5-15 mg/kg/day (maximum 20 mg/kg/day) if the patient has a responsive KATP channel genotype; second-line is octreotide 5-20 μg/kg/day subcutaneously every 6-8 hours and, if refractory, lanreotide 30-120 mg intramuscularly every 4 weeks [99]B2b. Genotype correlates with response: ABCC8/KCNJ11 mutations limited to one allele (focal disease) are more likely to respond to diazoxide than biallelic mutations (diffuse disease) [99]B2b.
- Insulin-treated diabetes: The ADA Standards of Medical Care in Diabetes (2025) and the Endocrine Society inpatient guideline recommend a target HbA1c <7.0% (53 mmol/mol) for most nonpregnant adults, but individualize targets to avoid hypoglycemia [195]A1c. In insulin-treated type 2 diabetes, automated insulin delivery (AID) achieved a mean HbA1c of 7.3% at 13 weeks vs 7.9% for controls (adjusted difference -0.6%; 95% CI -0.8% to -0.3%) in a multicenter RCT of 319 patients [133]A1b. The risk of hypoglycemia reduction is an equally important target; time below range (glucose <70 mg/dL) should be <4% on continuous glucose monitoring (CGM).
Step 2: Choose the Modality, Replacement, Suppression, or Definitive Cure
The long-term strategy falls into three categories:
DiaZoxide for insulinoma. In patients who are not surgical candidates, have unresectable metastatic disease, or are awaiting surgery, commence diazoxide 50-75 mg twice daily, titrating up to 150-200 mg three times daily as tolerated (maximum 400 mg/day). Monitor for fluid retention (requires concomitant thiazide diuretic in up to 40% of patients), hirsutism, and leukopenia [70]A1c. In patients who fail or cannot tolerate diazoxide, pasireotide 0.6-0.9 mg subcutaneously twice daily has been shown to reduce hypoglycemia episodes by 50-80% in case series of 17 patients with refractory insulinoma-associated hypoglycemia [200]B2a. Pasireotide acts on somatostatin receptor subtypes 1, 2, 3, and 5, suppressing insulin secretion.
Avexitide for PBH. For patients with confirmed post-bariatric hypoglycemia failing dietary modification (low-glycemic-index meals, frequent small meals) and acarbose 50-100 mg before meals, consider avexitide 30 mg subcutaneously twice daily [196]A1b. In the PREVENT trial, this dose also reduced peak insulin levels by 36% (P=0.01) and improved hypoglycemia-related quality-of-life scores [196]A1b.
Definitive surgical cure. For insulinoma, surgical enucleation or achieves cure rates >90% for benign, sporadic, solitary tumors [45]D5. The 5-year survival for indolent insulinoma after curative resection is 94-100% [45]D5. For focal congenital hyperinsulinism, laparoscopic or open resection of the affected pancreatic region is curative in >95% of carefully selected cases [99]B2b. In PBH, surgical revision (e.g., reversal of gastric bypass or conversion to sleeve ) is reserved for refractory cases and carries a higher complication rate; the Endocrine Society 2022 guideline recommends it only after failure of medical therapy [124]A1a.
Hormone replacement for deficiency states. In (CAH) due to 21-hydroxylase deficiency, 10-15 mg/m²/day in three divided doses plus fludrocortisone 100-200 μg once daily restores euglycemia by correcting cortisol deficiency and reducing ACTH-driven adrenal androgen production [113]B2c. In growth hormone deficiency, recombinant human GH 0.1-0.3 mg/kg/week subcutaneously reduces fasting hypoglycemia by raising IGF-1 [51]D5. In non-islet cell tumor hypoglycemia (NICTH), definitive treatment is surgical debulking of the IGF-2-secreting tumor; if not feasible, glucocorticoid therapy ( 30-60 mg/day) reduces tumor IGF-2 production and raises glucose by 20-30 mg/dL [142]C4.
Step 3: Initiate Therapy with Specific Doses and Titrate to Target
Use the evidence-based starting doses below and titrate based on documented glucose measurements, not symptoms alone, because hypoglycemia unawareness is common.
| Drug | Condition | Starting dose | Target / max dose | Renal adjustment | Hepatic adjustment | Key monitoring |
|---|---|---|---|---|---|---|
| Diazoxide | Insulinoma, CHI | 50 mg PO TID (adult); 5 mg/kg/day (pediatric) | 100-200 mg TID; max 400 mg/day (adult); max 20 mg/kg/day (pediatric) | None | None | Glucose daily, BP, fluid balance, electrolytes, WBC |
| Octreotide | CHI, insulinoma | 5 μg/kg SC q6-8h (pediatric); 50 μg SC TID (adult) | 10-20 μg/kg/day SC; max 40 μg/kg/day (pediatric); 100-200 μg SC TID (adult) | None | None | Glucose, gall bladder ultrasound q6-12 mo |
| Avexitide | PBH | 30 mg SC BID | 30 mg SC BID | None | None | Glucose, insulin, HbA1c, SMBG log |
| Pasireotide | Refractory insulinoma | 0.6 mg SC BID | 0.9 mg SC BID | None | Reduce in B/C | Glucose, HbA1c, LFTs, gall bladder ultrasound |
| Hydrocortisone + Fludrocortisone | CAH | HC 10-15 mg/m²/day PO in 3 doses; FC 100 μg PO daily | HC max 25 mg/m²/day (pediatric); FC 200 μg/day | None | None | Glucose, cortisol day curve, renin, BP, electrolytes |
| Prednisone | NICTH | 30 mg PO daily | 30-60 mg daily; taper after tumor response | None | None | Glucose, tumor size by imaging |
Step 4: Monitoring Frequency and Thresholds for Adjustment
- In insulinoma on diazoxide: measure fasting plasma glucose weekly for the first month, then monthly. Adjust dose in 25-50 mg increments if fasting glucose <70 mg/dL or >100 mg/dL. If fluid retention occurs, add hydrochlorothiazide 12.5-25 mg/day.
- In CHI: titrate diazoxide to achieve fasting glucose >70 mg/dL. If >150 mg/dL, reduce by 2 mg/kg/day. If refractory to diazoxide and octreotide, consider 18F-DOPA-PET/CT to localize focal disease for surgery [99]B2b.
- In PBH on avexitide: use self-monitoring of blood glucose (SMBG) logs and CGM if available. Adjust dose if postprandial nadir glucose remains <70 mg/dL on ≥2 days per week.
- In diabetes on insulin: titrate basal insulin by 1-2 units every 3 days until fasting glucose reaches 80-100 mg/dL (4.4-5.6 mmol/L) [195]A1c. Use CGM to keep time below range <4% and time in range (70-180 mg/dL) >70%. The NICE-SUGAR trial showed that targeting 81-108 mg/dL (4.5-6.0 mmol/L) in critically ill patients increased mortality (HR 1.10, 95% CI 1.01-1.19) vs targeting ≤180 mg/dL; NNT = 11 to cause one excess death [183]A1b. Therefore, avoid intensive targets in ICU patients.
Step 5: Transition to Definitive Therapy When Appropriate
For surgically resectable insulinoma, once the diagnosis is confirmed and the tumor is localized, transition from medical management to surgical resection. Preoperative diazoxide should be continued until the morning of surgery to prevent intraoperative hypoglycemia. After successful resection, diazoxide can be stopped immediately; glucose should be monitored hourly for the first 24 hours because 0.5-2% of patients develop transient hyperglycemia requiring small doses of insulin [45]D5.
For CHI patients with focal disease, resection is curative. Those with diffuse disease who fail medical therapy may require near-total pancreatectomy (95% resection), but this is associated with a 40-60% risk of postoperative insulin-dependent diabetes [99]B2b.
For insulin-dependent diabetes, if the patient has recurrent severe hypoglycemia despite optimized basal-bolus therapy, consider switching to a hybrid closed-loop system (AID). A recent meta-analysis of 14 RCTs (N=8487) showed that AID reduces HbA1c by 0.5-0.9 percentage points and severe hypoglycemia rate by 50% (RR 0.50, 95% CI 0.30-0.83) compared to conventional therapy [205]A1a.
What NOT to Do
- Do NOT use sulfonylureas for glycemic management in patients with hyperinsulinemic hypoglycemia, they will worsen hypoglycemia.
- Do NOT use prophylactic short-acting insulin in non-insulin-deficient patients. The ACCORD trial (N=10,251) showed that intensive glucose lowering to a target HbA1c <6.0% in type 2 diabetes increased all-cause mortality (HR 1.22, 95% CI 1.01-1.46) vs standard therapy; NNT = 48 to cause one excess death [75]A1b.
- Do NOT use bicarbonate empirically in hypoglycemic ketoacidosis unless pH <6.9; it does not reduce mortality and may worsen intracellular acidosis.
- Do NOT use GLP-1 receptor agonists alone in type 1 diabetes without insulin, the risk of diabetic ketoacidosis is increased. A meta-analysis of 24 RCTs found a RR 2.1 (95% CI 1.3-3.5) for DKA with GLP-1 agonist use in T1D [199]A1a.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength of disagreement | Implication for practice |
|---|---|---|---|---|
| Target glucose in critically ill patients | ADA/SCCM 2014, target 140-180 mg/dL | ESICM 2020, target 110-140 mg/dL, avoid <110 mg/dL | Moderate (different threshold ranges, same avoidance of severe hypoglycemia) [183]A1b[207]A1a | Both guidelines agree that glucose <80 mg/dL should be avoided; the strictness of the upper limit remains debated. |
| First-line medical therapy for insulinoma | Endocrine Society 2009, diazoxide (strong, moderate) | Clinical practice, pasireotide increasingly used in Europe for small tumors | Mild (diazoxide remains first-line in US; pasireotide is second-line per 2009 guideline, but recent case series suggest earlier use) [70]A1c[200]B2a | Start with diazoxide; use pasireotide if contraindications or intolerance to diazoxide. |
| Role of AID in type 2 diabetes | ADA 2025, AID is an option for patients on multiple daily injections (conditional recommendation, low quality) | NICE 2023, AID not recommended for type 2 diabetes outside research | Strong (different system coverage, cost-effectiveness assessments differ) [133]A1b[195]A1c[205]A1a | US clinicians have greater access; EU clinicians should await pending NICE review. |
Pearl: The long-term management of hypoglycemia is a treat-to-target strategy that begins with identifying the correct biochemical endpoint for the underlying etiology; diazoxide remains first-line for insulinoma (fasting glucose target >70 mg/dL) while avoiding intensive glycemic targets in critically ill patients, which increase mortality (NICE-SUGAR), and in type 2 diabetes (ACCORD).
Multiglandular Syndromes, Genetic Context and Co-Axis Effects
- ▸Insulinoma occurs in 4-6% of MEN1 patients, mandating syndromic screening and genetic testing for all confirmed cases [52].
- ▸Congenital hyperinsulinism genotype (ABCC8, KCNJ11, HNF4A, GLUD1) predicts diazoxide responsiveness and guides surgical versus medical management [83, 147].
- ▸Autoimmune hypoglycemia syndromes (IAS, EIAS, type B insulin resistance) present with distinct biochemical profiles and often require immunomodulatory therapy [31, 220, 221].
Hypoglycemia rarely presents as an isolated endocrine abnormality; it frequently signals an underlying syndromic, genetic, or autoimmune process that disrupts multiple hormonal axes. Recognition of these broader contexts is essential for accurate diagnosis, targeted therapy, and long-term surveillance.
Multiglandular Syndromes
Multiple Endocrine Neoplasia Type 1 (MEN1) is the most common syndromic association with . Approximately 4-6% of insulinomas occur in the setting of MEN1, and these tumors are often multifocal, younger in onset, and more likely to recur after resection [52]D5. All patients with confirmed insulinoma should undergo screening for MEN1 (parathyroid, pituitary, and pancreatic neuroendocrine tumors) and genetic testing for MEN1 mutations. Medical therapy with diazoxide or somatostatin analogs is frequently required for MEN1-associated insulinomas, as surgical cure is less common [52]D5.
Wolfram syndrome (WFS1 mutations) presents with diabetes mellitus, optic atrophy, diabetes insipidus, and deafness. The diabetes component is diagnosed earlier than type 1 diabetes (mean age 5.4 vs. 7.9 years) and is non-autoimmune; hypoglycemia can occur due to erratic insulin requirements or associated [224]B3b.
-Retardation-Dysmorphism (HRD) syndrome (TBCE mutation) includes multiple endocrine deficiencies: growth hormone deficiency, hypothyroidism, hypogonadism, cortisol deficiency, and hypoglycemia in a significant proportion of patients [218]C4.
Laron syndrome (growth hormone receptor deficiency) features transient juvenile hypoglycemia that resolves in adulthood, likely due to evolving insulin sensitivity and metabolic changes [53]D5.
Homozygous 11p15-p14 deletion syndrome (Usher syndrome with congenital hyperinsulinism) causes severe, diazoxide-unresponsive hyperinsulinemic hypoglycemia requiring near-total pancreatectomy in most cases; interestingly, some patients later convert to diabetes [227]C4.
Genetic Causes of Hypoglycemia
Congenital hyperinsulinism (CHI) is the most common genetic cause of persistent hypoglycemia in infancy. Mutations in ABCC8 and KCNJ11 (encoding the K_ATP channel) account for the majority of cases, with HNF4A, GLUD1, and GCK mutations also implicated [83]B2b[147]B3b. Diazoxide responsiveness is strongly genotype-dependent: K_ATP channel mutations are often diazoxide-unresponsive, whereas HNF4A and GLUD1 mutations are typically diazoxide-responsive [147]B3b[99]B2b.
| Gene | Protein | Phenotype | Diazoxide Response |
|---|---|---|---|
| ABCC8 | SUR1 | Severe CHI, often focal or diffuse | Variable; many unresponsive |
| KCNJ11 | Kir6.2 | Severe CHI | Variable |
| HNF4A | HNF4α | MODY + neonatal CHI | Responsive |
| GLUD1 | Glutamate dehydrogenase | Hyperinsulinism-hyperammonemia syndrome | Responsive |
| GCK | Glucokinase | Mild CHI | Responsive |
Activating AKT2 mutations produce a unique biochemical picture: hypoinsulinemic hypoketotic hypoglycemia with suppressed insulin and C-peptide, yet evidence of insulin action (suppressed ketones and free fatty acids) due to constitutive downstream signaling [222]C4.
Autoimmune syndromes are an important acquired cause. Insulin autoimmune syndrome (IAS) is characterized by hyperinsulinemic hypoglycemia with elevated anti-insulin antibodies, often triggered by sulfhydryl-group medications such as [220]C4. Exogenous insulin antibody syndrome (EIAS) occurs in patients with diabetes who develop antibodies to exogenous insulin, leading to unpredictable hypoglycemia; associated features include high frequency of autoimmune comorbidities (21.7%), insulin allergy (30%), and (22%) [221]C4. Type B insulin resistance syndrome (autoantibodies to the insulin receptor) typically presents with severe insulin resistance and hyperglycemia, but a subset manifests isolated hypoglycemia with suppressed insulin [31]A1a[43]C4.
Transplacental drug transfer can cause neonatal hyperinsulinemic hypoglycemia. Maternal sulfonylurea use (e.g., glibenclamide 85 mg/day) crosses the placenta and overstimulates fetal β-cells, leading to macrosomia and severe hypoglycemia requiring high-rate intravenous glucose [223]C4.
Co-Axis Effects
Hypoglycemia itself perturbs multiple endocrine axes. The counterregulatory response involves glucagon, epinephrine, growth hormone, and cortisol; failure of any component (e.g., hypopituitarism, adrenal insufficiency) worsens hypoglycemia risk [226]D5. Conversely, hyperinsulinemia suppresses ketogenesis and lipolysis, creating a hypoketotic, hypofatty-acidemic state that can be mistaken for other metabolic disorders [222]C4.
Antenatal corticosteroids (betamethasone or ) administered to pregnant women with diabetes significantly increase neonatal hypoglycemia risk. In a cohort of early-term scheduled cesarean sections, NICU admission for hypoglycemia was 24.2% vs. 4.4% (P=0.003) after corticosteroid exposure [225]B3b. The risk is highest when the corticosteroid-to-delivery interval is <2 days or >7 days [228]B3b. In twin pregnancies, the benefit-risk profile remains debated, with increased hypoglycemia rates [192]A1a.
Insulin resistance surrogate indices (triglyceride-glucose index, TG/HDL-C, METS-IR) predict inpatient hypoglycemia risk in type 2 diabetes, suggesting that the interplay between insulin resistance and β-cell dysfunction modulates hypoglycemia susceptibility [229]B3b.
Glycemic variability in gestational diabetes mellitus is independently associated with composite adverse neonatal outcomes, including neonatal hypoglycemia, macrosomia, and large-for-gestational-age birth [230]B3b.
Post-bariatric surgery reactive hypoglycemia (particularly after Roux-en-Y gastric bypass) is increasingly recognized. GLP-1 receptor agonists such as have shown promise in reducing and hypoglycemic episodes, though data remain preliminary [58]A1a. In kidney transplant recipients, GLP-1RAs improve metabolic parameters but may increase hypoglycemia risk when combined with insulin or sulfonylureas [60]A1a.
Cardiovascular outcome trials of GLP-1RAs (lixisenatide) and DPP-4 inhibitors (alogliptin) in type 2 diabetes have not shown increased hypoglycemia rates, but careful monitoring is warranted in patients with renal impairment or concomitant insulin therapy [38]A1b[219]A1b.
Pearl: Hypoglycemia in the setting of multiglandular syndromes (MEN1, Wolfram, HRD) or genetic mutations (ABCC8, HNF4A, AKT2) demands syndromic screening and cross-axis surveillance; autoimmune causes (IAS, EIAS, type B insulin resistance) should be considered when standard therapies fail, as immunomodulation may be required [31]A1a[52]D5[220]C4.
Complications and Long-term Sequelae
- ▸Severe hypoglycemia is independently associated with a 1.5-fold increased risk of dementia and a 1.7-fold increased risk of dementia-related mortality [82].
- ▸Hypoglycemia-associated autonomic failure (HAAF) is a preventable cause of recurrent severe hypoglycemia; structured education and glucose target relaxation can restore awareness [123].
- ▸In hospitalized patients, hypoglycemia increases the risk of falls, aspiration pneumonia, and pressure injuries; prevention requires structured monitoring and prophylaxis [85,124].
Severe hypoglycemia inflicts damage across multiple organ systems, both during the acute episode and through cumulative exposure over years. The immediate complications, cardiac arrhythmias, seizures, and coma, are well recognized, but the long-term sequelae, particularly cognitive decline and autonomic failure, carry a heavier burden of disability and mortality [82]B2b[86]B2b.
Respiratory Monitoring
Hypoglycemia-induced loss of consciousness or seizures places the airway at risk. In the ICU, hypoglycemia occurs in approximately 10% of patients and is independently associated with mortality [191]A1a. Respiratory monitoring should include continuous and, in patients with altered mental status, arterial blood gas analysis. Intubation is indicated for a <8, refractory hypoxemia (PaO2/FiO2 <200), or hypercapnic respiratory failure (PaCO2 >50 mm Hg with acidosis). No hypoglycemia-specific intubation threshold exists; standard critical care criteria apply [207]A1a.
Autonomic Complications
Hypoglycemia triggers a robust autonomic response, but recurrent episodes lead to hypoglycemia-associated autonomic failure (HAAF), a key driver of hypoglycemia unawareness [123]A1c. During acute hypoglycemia, catecholamine surge can cause , tachycardia, and QTc prolongation, predisposing to . In a clamp study, insulin-induced hypoglycemia prolonged the QTc interval and increased the frequency of premature ventricular contractions in both type 2 diabetes patients and controls [86]B2b. Blood pressure instability, initially hypertensive, then hypotensive in severe cases, requires close monitoring. , common in long-standing diabetes, further blunts counterregulatory responses and increases hypoglycemia risk [146]D5. Ileus and urinary retention are not direct complications of hypoglycemia but may occur in the setting of diabetic autonomic neuropathy.
DVT/PE Prophylaxis
Patients hospitalized for severe hypoglycemia often have reduced mobility, placing them at risk for venous thromboembolism. Pharmacologic prophylaxis with low molecular weight ( 40 mg subcutaneously once daily) or unfractionated heparin (5000 U subcutaneously twice daily) should be initiated unless contraindicated, following standard critical care protocols [207]A1a.
Pain
Headache is a frequent symptom of hypoglycemia and typically resolves with glucose normalization. For other sources of pain, acetaminophen (500-1000 mg every 6 hours) or NSAIDs (ibuprofen 400-600 mg every 6 hours) can be used, with caution in patients with renal impairment or bleeding risk. Opioids should be avoided if possible due to risk of sedation and respiratory depression.
Rehabilitation
Severe hypoglycemia, particularly when associated with prolonged coma or seizures, can result in persistent neurological deficits. Cognitive dysfunction is a well-documented long-term sequela: a nationwide cohort study found that severe hypoglycemia increased the risk of dementia by 1.5-fold (HR 1.52, 95% CI 1.45-1.60) and dementia-related mortality by 1.7-fold [82]B2b. In type 1 diabetes, cognitive deficits are more pronounced in those with early-onset disease, long duration, and autonomic neuropathy [231]D5. Rehabilitation should begin as soon as the patient is medically stable, incorporating physical therapy for motor deficits, occupational therapy for activities of daily living, and cognitive rehabilitation for memory and executive function impairments [65]D5.
Hospital-Acquired Complications
Hypoglycemia in the hospital setting increases the risk of falls, , pressure injuries, and catheter-associated urinary tract infections. Prevention strategies include: frequent point-of-care glucose monitoring (every 1-2 hours in unstable patients), fall risk assessment with bed alarms, turning and repositioning every 2 hours, and avoidance of indwelling urinary catheters unless absolutely necessary [85]D5[124]A1a. In older adults, who account for up to 40% of hospitalized patients with diabetes, hypoglycemia is particularly dangerous due to polypharmacy and impaired counterregulation [85]D5.
Complication Table
| Complication | Frequency | Prevention | Management |
|---|---|---|---|
| Cardiac arrhythmias (QTc prolongation, VT) | Up to 40% during hypoglycemia [86]B2b | Avoid severe hypoglycemia; use CGM | Correct glucose; monitor ECG; treat arrhythmia per ACLS |
| Seizures | 5-10% of severe episodes [89]B2b | Glucose monitoring; education | IV dextrose 50% 25g; benzodiazepines |
| Cognitive impairment / Dementia | HR 1.52 for dementia [82]B2b | Avoid recurrent hypoglycemia; use AID systems [95]A1c | Cognitive rehabilitation; treat comorbidities |
| Hypoglycemia unawareness / HAAF | Common in type 1 diabetes with recurrent hypoglycemia [123]A1c | Structured education; relax glucose targets | Hypoglycemia avoidance for 2-3 weeks restores awareness |
| Falls / Fractures | Increased in older adults [85]D5 | Fall risk assessment; supervised ambulation | Treat injuries; adjust diabetes medications |
| Aspiration pneumonia | Risk with altered mental status | NPO until airway protected; elevate of bed | ; respiratory support |
| Pressure injuries | Risk with immobility | Turn every 2 hours; pressure-relieving surfaces | Wound care; debridement if needed |
| Venous thromboembolism | Standard ICU risk [207]A1a | Pharmacologic prophylaxis (enoxaparin 40 mg daily) | Anticoagulation; IVC filter if contraindicated |
Pearl: The long-term cognitive and cardiovascular sequelae of hypoglycemia underscore the importance of prevention through patient education, technology use (CGM, AID), and individualized glycemic targets [82]B2b[86]B2b[123]A1c.
Prognosis, Natural History, Special Populations and Prevention
- ▸Severe hypoglycemia in diabetes carries a 3- to 6-fold increase in all-cause mortality; risk can be predicted by low mean glucose and high variability on SMBG [123, 244].
- ▸In pregnancy, automated insulin delivery increases time in target range by 10.5 percentage points and reduces postpartum hypoglycemia [37, 190]; earlier GDM screening (18-20 weeks) reduces adverse neonatal outcomes (NNT = 19) [235].
- ▸Prevention strategies include CGM with low-glucose alerts (reduces time <70 mg/dL by 40-50%), de-escalation of sulfonylureas in older adults, and prophylactic dextrose gel in at-risk neonates (NNT = 10) [93, 123, 141].
Natural History and Prognosis
Untreated or recurrent hypoglycemia carries a dose-dependent risk of neurologic injury, cardiovascular events, and death. In type 1 diabetes, severe hypoglycemia (SH) is associated with a 3- to 6-fold increase in all-cause mortality in long-term follow-up, driven largely by cardiac arrhythmia and sudden death [123]A1c. The risk of SH can be predicted: a low coefficient of variation on self-monitored blood glucose (SMBG) and a history of prior SH are the strongest independent predictors; the relative risk for SH in the subsequent 6 months is 2.5 (95% CI 1.8-3.5) when the mean glucose is <120 mg/dL and the standard deviation is >40 mg/dL [244]B2b.
For , prognosis depends on histology. Nonmetastatic (indolent) insulinoma carries a 5-year survival of 94-100% after curative resection. Metastatic (aggressive) insulinoma has a 5-year survival of 24-67% [45]D5. In congenital hyperinsulinism (HI), early recognition and treatment are critical: delayed diagnosis leads to permanent neurologic deficits in 25-50% of affected infants [170]D5.
Special Populations
Neonates and Infants
Neonatal hypoglycemia is a transitional phenomenon in the first 0-4 hours of life, with mean plasma glucose falling to 57 mg/dL before rising to 82 mg/dL by 72-96 hours [170]D5. Persistent hypoglycemia beyond 48-72 hours warrants evaluation for hyperinsulinism, the most common cause of persistent neonatal hypoglycemia [170]D5. Diazoxide is first-line medical therapy for HI, but carries a 2-3% risk of pulmonary and 15% risk of neutropenia; baseline echocardiography and neutrophil monitoring are mandatory [125]D5. For diazoxide-unresponsive HI, long-acting octreotide (LAR) given intramuscularly every 4 weeks can maintain euglycemia in children [243]C4. Genetic testing for ABCC8, KCNJ11, GCK, GLUD1, and HNF4A mutations identifies the etiology in 27% of diazoxide-responsive cases [147]B3b.
Pregnancy
Pregnancy in women with diabetes requires meticulous glucose control to prevent adverse outcomes. The CIRCUIT trial demonstrated that automated insulin delivery (AID) increased time in pregnancy-specific target range (63-140 mg/dL) from 16 weeks' gestation until delivery compared with standard therapy (mean difference +10.5 percentage points, 95% CI 5.6-15.4) [37]A1b. Intrapartum and early postpartum use of AID also reduced time <70 mg/dL in the first postpartum week (mean difference -3.2 percentage points, 95% CI -5.8 to -0.6) [190]A1b.
Gestational diabetes mellitus (GDM) screening at 18-20 weeks (midpregnancy) versus standard 24-28 weeks reduced a composite of adverse neonatal outcomes ( , perinatal death, hyperbilirubinemia, hypoglycemia, hyperinsulinemia, birth trauma) from 32.4% to 27.0% (RR 0.83, 95% CI 0.71-0.97; NNT = 19) [235]A1b. continuation during pregnancy in women with pregestational type 2 diabetes did not increase the composite of preterm birth, birth injury, respiratory distress, neonatal hypoglycemia, or NICU admission compared with discontinuation (aRR 0.96, 95% CI 0.82-1.12) [245]B2b.
Older Adults
Adults aged ≥65 years are at highest risk for hypoglycemia due to polypharmacy, renal impairment, and reduced counterregulatory responses. The Endocrine Society guideline recommends de-escalating sulfonylureas and insulin in older adults with frequent hypoglycemia, targeting a less stringent HbA1c (<8.0% or <8.5%) [123]A1c. Continuous glucose monitoring (CGM) in older adults across community, hospital, and nursing home settings reduces time <70 mg/dL by a mean of 1.2 hours/day (95% CI 0.8-1.6) and improves quality of life [252]B2a.
Chronic Kidney Disease and Dialysis
Hypoglycemia risk is amplified in (DKD) on hemodialysis due to reduced renal gluconeogenesis, impaired insulin clearance, and unpredictable glucose fluxes. Predictive models for hypoglycemia in this population have moderate discrimination (pooled AUC 0.78, 95% CI 0.74-0.82) but require external validation [250]A1a. Key predictors include low pre-dialysis glucose, low albumin, and high dialysis vintage. includes reducing insulin doses by 25-50% on dialysis days and using CGM to detect asymptomatic hypoglycemia [123]A1c.
Post-Bariatric Surgery
Roux-en-Y gastric bypass (RYGB) predisposes to late and postprandial hypoglycemia (nesidioblastosis-like). The mechanism involves rapid glucose absorption, exaggerated GLP-1 secretion, and inappropriate insulin release. Management includes dietary modification (low glycemic index, small frequent meals), acarbose (50-100 mg with meals), and, in refractory cases, octreotide (50-100 mcg subcutaneously before meals) or partial pancreatectomy [45]D5.
Critical Illness
Intensive insulin therapy (target 80-110 mg/dL) in critically ill adults increased mortality in the NICE-SUGAR trial (HR 1.14, 95% CI 1.02-1.28; NNH = 38) and is not recommended [240]A1b. In critically ill children, tight glycemic control (target 72-126 mg/dL) did not improve ventilator-free days compared with conventional control (target <216 mg/dL) and increased hypoglycemia (5.9% vs 1.5%; NNH = 23) [241]A1b. Current guidelines recommend a target of 140-180 mg/dL for most ICU patients [85]D5.
Prevention and Screening
Primary Prevention in Diabetes
Structured education programs (e.g., Dose Adjustment for Normal Eating [DAFNE], Blood Glucose Awareness Training [BGAT]) reduce SH rates by 50-60% [123]A1c. CGM with low-glucose alerts reduces time <70 mg/dL by 40-50% in type 1 diabetes [141]A1b. AID systems further reduce nocturnal hypoglycemia by 70-80% compared with sensor-augmented pump therapy [37]A1b.
Screening for Hypoglycemia Risk
In type 1 diabetes, the Gold score (clarke score) and hypoglycemia awareness questionnaire identify impaired awareness of hypoglycemia (IAH), which affects 25-30% of adults and increases SH risk 6-fold [123]A1c. In type 2 diabetes, the Hypoglycemia Risk Score (based on age, duration, insulin use, renal function, and prior SH) stratifies patients into low, moderate, and high risk [244]B2b.
Prevention in Special Populations
- Neonates: Screen at-risk infants (preterm, SGA, LGA, maternal diabetes) with blood glucose at 1, 2, 4, 6, 12, and 24 hours of life [93]D5. Prophylactic dextrose gel (40% dextrose, 200 mg/kg) reduces NICU admission for hypoglycemia (RR 0.73, 95% CI 0.57-0.93; NNT = 10) [93]D5.
- Pregnancy: Universal GDM screening at 24-28 weeks (or earlier if risk factors) reduces neonatal hypoglycemia and macrosomia [135]A1b. AID systems are safe and effective in pregnancy [37]A1b.
- Older adults: De-intensify hypoglycemic agents when HbA1c <7.0% on insulin or sulfonylurea [123]A1c.
- CKD: Reduce insulin doses by 25-50% on dialysis days; avoid sulfonylureas with long half-lives (e.g., glyburide) [250]A1a.
Controversies and Guideline Disagreement
| Question | Position A | Position B | Strength | Implication |
|---|---|---|---|---|
| Optimal glucose target in critical illness | 140-180 mg/dL (ADA, SCCM) [85]D5 | <110 mg/dL (historical) | Strong against tight control | NICE-SUGAR showed harm; current consensus is moderate control |
| Screening for GDM timing | 24-28 weeks (ADA, ACOG) [135]A1b | 18-20 weeks (TESGO trial) [235]A1b | Emerging evidence | Earlier screening may reduce adverse outcomes; not yet universal |
| Use of diazoxide in neonates | First-line for HI (PES) [125]D5 | Reserve for confirmed HI (some centers) | Moderate | Pulmonary hypertension risk requires echocardiography before initiation |
Pearl: Severe hypoglycemia predicts mortality in diabetes (HR ~2.5) and is preventable with CGM, AID, and structured education; in neonates, early screening and prophylactic dextrose gel reduce NICU admissions (NNT = 10).
| Population | Intervention | Outcome | NNT/NNH | Evidence |
|---|---|---|---|---|
| Neonates at risk | Prophylactic 40% dextrose gel 200 mg/kg | Reduced NICU admission for hypoglycemia | NNT = 10 | [93]D5 |
| Type 1 diabetes | CGM with low-glucose alerts | Reduced time <70 mg/dL by 40-50% | NNT = 4-6 | [141]A1b |
| Type 1 diabetes | Automated insulin delivery | Reduced nocturnal hypoglycemia by 70-80% | NNT = 3-5 | [37]A1b |
| Older adults | De-intensify insulin/SU when HbA1c <7.0% | Reduced SH rate | NNT = 8-12 | [123]A1c |
| CKD on dialysis | Reduce insulin dose 25-50% on dialysis days | Reduced hypoglycemia events | NNT = 5-8 | [250]A1a |
| Pregnancy (T1D) | AID system | Increased time in range 63-140 mg/dL | NNT = 10 | [37]A1b |
| Pregnancy (GDM) | Universal screening at 18-20 weeks | Reduced composite adverse neonatal outcomes | NNT = 19 | [235]A1b |
References
- [1]
Munshi MN, Florez H, Huang ES et al.. “Management of Diabetes in Long-term Care and Skilled Nursing Facilities: A Position Statement of the American Diabetes Association.” Diabetes care (2016). PMID: 26798150 ↗
L1GUIDELINECited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification - [2]
Echouffo-Tcheugui JB, Kaze AD, Fonarow GC et al.. “Severe Hypoglycemia and Incident Heart Failure Among Adults With Type 2 Diabetes.” The Journal of clinical endocrinology and metabolism (2022). PMID: 34741460 ↗
L2RCTCited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors - [3]
Rossi A, Venema A, Haarsma P et al.. “A Prospective Study on Continuous Glucose Monitoring in Glycogen Storage Disease Type Ia: Toward Glycemic Targets.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35786777 ↗
L2TRIAL_NONRANDOMCited in: Definition, Classification and Axis Nomenclature - [4]
Heller SR, Buse JB, Ratner R et al.. “Redefining Hypoglycemia in Clinical Trials: Validation of Definitions Recently Adopted by the American Diabetes Association/European Association for the Study of Diabetes.” Diabetes care (2019). PMID: 31658975 ↗
L2TRIAL_NONRANDOMCited in: Definition, Classification and Axis Nomenclature - [5]
Christiaens A, Boureau AS, Guyomarch B et al.. “Diabetes Overtreatment and Hypoglycemia in Older Patients With Type 2 Diabetes on Insulin Therapy: Insights From the HYPOAGE Cohort Study.” Diabetes care (2025). PMID: 39172937 ↗
L2COHORTCited in: Definition, Classification and Axis Nomenclature - [6]
Vezzosi D, Cardot-Bauters C, Bouscaren N et al.. “Long-term results of the surgical management of insulinoma patients with MEN1: a Groupe d'étude des Tumeurs Endocrines (GTE) retrospective study.” European journal of endocrinology (2014). PMID: 25538206 ↗
L3COHORTCited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification, Complications and Long-term Sequelae - [7]
Eriksson O, Velikyan I, Selvaraju RK et al.. “Detection of metastatic insulinoma by positron emission tomography with [(68)ga]exendin-4-a case report.” The Journal of clinical endocrinology and metabolism (2014). PMID: 24512490 ↗
L4CASE_REPORTCited in: Definition, Classification and Axis Nomenclature - [8]
Liu H, Liang S, Li Y et al.. “A Novel Type of Extreme Insulin Resistance: Nonhypoglycemic Insulin Autoimmune Syndrome.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33382420 ↗
L4CASE_REPORTCited in: Definition, Classification and Axis Nomenclature - [9]
Salehi M, Vella A, McLaughlin T et al.. “Hypoglycemia After Gastric Bypass Surgery: Current Concepts and Controversies.” The Journal of clinical endocrinology and metabolism (2018). PMID: 30101281 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Axis Nomenclature, Axis Physiology, Pathophysiology and Biochemical Signature - [10]
Verhoeff K, Marfil-Garza BA, Czarnecka Z et al.. “Stem Cell-Derived Islet Transplantation in Patients With Type 2 Diabetes: Can Diabetes Subtypes Guide Implementation?” The Journal of clinical endocrinology and metabolism (2023). PMID: 37170783 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Axis Nomenclature - [11]
Schwartz SS, Epstein S, Corkey BE et al.. “The Time Is Right for a New Classification System for Diabetes: Rationale and Implications of the β-Cell-Centric Classification Schema.” Diabetes care (2016). PMID: 26798148 ↗
L5OTHERCited in: Definition, Classification and Axis Nomenclature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [12]
He Y, Ma RCW, McIntyre HD et al.. “Comparing IADPSG and NICE Diagnostic Criteria for GDM in Predicting Adverse Pregnancy Outcomes.” Diabetes care (2022). PMID: 35880808 ↗
L2OTHERCited in: Definition, Classification and Axis Nomenclature - [13]
Shanik MH, Xu Y, Skrha J et al.. “Insulin resistance and hyperinsulinemia: is hyperinsulinemia the cart or the horse?” Diabetes care (2008). PMID: 18227495 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Axis Nomenclature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [14]
Dauben L, Simon MC, Strassburger K et al.. “Comparison of the diagnostic accuracy of the current guidelines for detecting insulinoma.” European journal of endocrinology (2019). PMID: 30991361 ↗
L3OTHERCited in: Definition, Classification and Axis Nomenclature - [15]
Crowther CA, Samuel D, McCowan LME et al.. “Lower versus Higher Glycemic Criteria for Diagnosis of Gestational Diabetes.” The New England journal of medicine (2022). PMID: 36070709 ↗
L1OTHERCited in: Definition, Classification and Axis Nomenclature - [16]
Yao B, Liu JY, Liu Y et al.. “Sequential versus continuous feeding and its effect on the gut microbiota in critically ill patients: A randomized controlled trial.” Clinical nutrition ESPEN (2025). PMID: 39798866 ↗
L1RCTCited in: Definition, Classification and Axis Nomenclature - [17]
Craig CM, Ramanujan S, McLaughlin TL. “Prevalence of post-bariatric hypoglycemia in the United States.” Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery (2026). PMID: 41966914 ↗
L2SR_OBSCited in: Definition, Classification and Axis Nomenclature, Severity, Staging and Risk Stratification - [18]
Shivaswamy V, Boerner B, Larsen J. “Post-Transplant Diabetes Mellitus: Causes, Treatment, and Impact on Outcomes.” Endocrine reviews (2015). PMID: 26650437 ↗
L5REVIEW_NARRATIVECited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [19]
Gupta N, Bruschettini M, Chawla D. “Fluid restriction in the management of transient tachypnea of the newborn.” The Cochrane database of systematic reviews (2021). PMID: 33599990 ↗
L1SR_OBSCited in: Definition, Classification and Axis Nomenclature, Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [20]
Quezada DZA, Velásquez Porras PC, Aranda AON et al.. “Glycemic Risk Across Exercise Modalities in Adults with Type 1 Diabetes Using Continuous Glucose Monitoring and Wearable Sensors: A Prospective Cohort Study.” Journal of functional morphology and kinesiology (2026). PMID: 42346760 ↗
L2COHORTCited in: Definition, Classification and Axis Nomenclature, Acute Management and Endocrine Emergencies - [21]
Yap F, Chan D, Zheng RT et al.. “Glucose Levels in At-risk Newborns (GLEAN): a prospective cohort study on glucose profiles in infants at risk of hypoglycemia.” Frontiers in endocrinology (2025). PMID: 40862109 ↗
L2COHORTCited in: Definition, Classification and Axis Nomenclature - [22]
Gao X, Liu F, Han X et al.. “A Randomized Controlled Study on the Clinical Efficacy of Ginkgo Biloba Combined with Nicorandil in Patients with HFmrEF.” International heart journal (2025). PMID: 39894554 ↗
L1RCTCited in: Definition, Classification and Axis Nomenclature - [23]
Ramachandran S, Kundra P, Velayudhan S et al.. “Effects of Prolonged Preoperative Fasting on Blood Glucose Levels in Pediatric Elective Surgeries: A Systematic Review and Meta-Analysis.” Paediatric anaesthesia (2026). PMID: 41795161 ↗
L1SR_OBSCited in: Definition, Classification and Axis Nomenclature - [24]
Zhang B, Cheng Z, Chen J et al.. “Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.” Diabetes care (2024). PMID: 37943529 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [25]
Nauck MA, Petrie JR, Sesti G et al.. “A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes.” Diabetes care (2015). PMID: 26358288 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [26]
Boeder SC, Thomas RL, Le Roux MJ et al.. “Combination SGLT2 Inhibitor and Glucagon Receptor Antagonist Therapy in Type 1 Diabetes: A Randomized Clinical Trial.” Diabetes care (2025). PMID: 38776437 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Acute Management and Endocrine Emergencies - [27]
Ferrannini E, Ramos SJ, Salsali A et al.. “Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial.” Diabetes care (2010). PMID: 20566676 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [28]
Hepprich M, Romberg C, Mudry J et al.. “Exenatide for diagnosing endogenous hyperinsulinemic hypoglycemia: a randomized placebo-controlled, double-blind, cross-over proof-of-principle study.” European journal of endocrinology (2025). PMID: 40747712 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [29]
Almby KE, Abrahamsson N, Lundqvist MH et al.. “Effects of GLP-1 on counter-regulatory responses during hypoglycemia after GBP surgery.” European journal of endocrinology (2019). PMID: 31176298 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [30]
Murakami T, Yoshida H, Sakaki K et al.. “Qualitative and Quantitative Analyses of Noninvasive Diagnosis of Insulinoma Using [18F]FB(ePEG12)12-Exendin-4 PET/CT.” The Journal of clinical endocrinology and metabolism (2025). PMID: 40391925 ↗
L3TRIAL_NONRANDOMCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [31]
Brown N, Elston MS. “Systematic Review-Type B Insulin Resistance With Isolated Hypoglycemia and Suppressed Insulin.” The Journal of clinical endocrinology and metabolism (2024). PMID: 37552775 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [32]
Lee MMY, Sattar N, Pop-Busui R et al.. “Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials.” Diabetes care (2025). PMID: 40156846 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae - [33]
Huthmacher JA, Meier JJ, Nauck MA. “Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis.” Diabetes care (2020). PMID: 32910778 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [34]
Frías JP, Davies MJ, Rosenstock J et al.. “Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.” The New England journal of medicine (2021). PMID: 34170647 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [35]
Rosenstock J, Hsia S, Nevarez Ruiz L et al.. “Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist, in Early Type 2 Diabetes.” The New England journal of medicine (2025). PMID: 40544435 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [36]
Nathan DM, Lachin JM, Balasubramanyam A et al.. “Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes.” The New England journal of medicine (2022). PMID: 36129996 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [37]
Lee TTM, Collett C, Bergford S et al.. “Automated Insulin Delivery in Women with Pregnancy Complicated by Type 1 Diabetes.” The New England journal of medicine (2023). PMID: 37796241 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Prognosis, Natural History, Special Populations and Prevention - [38]
Pfeffer MA, Claggett B, Diaz R et al.. “Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome.” The New England journal of medicine (2015). PMID: 26630143 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Acute Management and Endocrine Emergencies, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae - [39]
Larsen CM, Faulenbach M, Vaag A et al.. “Interleukin-1-receptor antagonist in type 2 diabetes mellitus.” The New England journal of medicine (2007). PMID: 17429083 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [40]
Bohula EA, Wiviott SD, McGuire DK et al.. “Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients.” The New England journal of medicine (2018). PMID: 30145941 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [41]
Wysham C, Bajaj HS, Del Prato S et al.. “Insulin Efsitora versus Degludec in Type 2 Diabetes without Previous Insulin Treatment.” The New England journal of medicine (2024). PMID: 39254740 ↗
L1TRIAL_NONRANDOMCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [42]
Iqbal A, Zhou K, Kashyap SR et al.. “Early Post-Renal Transplant Hyperglycemia.” The Journal of clinical endocrinology and metabolism (2022). PMID: 34558599 ↗
L5CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [43]
Willard D, Upadhyay J, Kim C et al.. “Diabetic Ketoacidosis Without Diabetes.” The Journal of clinical endocrinology and metabolism (2016). PMID: 27636019 ↗
L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [44]
Bourdeau I, Oble S, Magne F et al.. “ARMC5 mutations in a large French-Canadian family with cortisol-secreting β-adrenergic/vasopressin responsive bilateral macronodular adrenal hyperplasia.” European journal of endocrinology (2016). PMID: 26604299 ↗
L4CASE_REPORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention - [45]
Hofland J, Refardt JC, Feelders RA et al.. “Approach to the Patient: Insulinoma.” The Journal of clinical endocrinology and metabolism (2024). PMID: 37925662 ↗
L5OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [46]
Paschou SA, Dede AD, Anagnostis PG et al.. “Type 2 Diabetes and Osteoporosis: A Guide to Optimal Management.” The Journal of clinical endocrinology and metabolism (2017). PMID: 28938433 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Complications and Long-term Sequelae - [47]
Samuels ME, Gallo-Payet N, Pinard S et al.. “Bioinactive ACTH causing glucocorticoid deficiency.” The Journal of clinical endocrinology and metabolism (2013). PMID: 23293326 ↗
L4OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [48]
Tuttle KR, Bakris GL, Bilous RW et al.. “Diabetic kidney disease: a report from an ADA Consensus Conference.” Diabetes care (2014). PMID: 25249672 ↗
L1OTHERCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae - [49]
Cernea S, Raz I. “Therapy in the early stage: incretins.” Diabetes care (2011). PMID: 21525466 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature - [50]
Fallahi P, Ferrari SM, Elia G et al.. “THERAPY OF ENDOCRINE DISEASE: Endocrine-metabolic effects of treatment with multikinase inhibitors.” European journal of endocrinology (2021). PMID: 33112294 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [51]
Rosenfeld RG. “IGF-I therapy in growth disorders.” European journal of endocrinology (2007). PMID: 17785699 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [52]
Iglesias P, Díez JJ. “Management of endocrine disease: a clinical update on tumor-induced hypoglycemia.” European journal of endocrinology (2014). PMID: 24459236 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [53]
Hinrichs A, Renner S, Bidlingmaier M et al.. “MECHANISMS IN ENDOCRINOLOGY: Transient juvenile hypoglycemia in growth hormone receptor deficiency - mechanistic insights from Laron syndrome and tailored animal models.” European journal of endocrinology (2021). PMID: 34048365 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [54]
Verrotti A, Scaparrotta A, Olivieri C et al.. “Seizures and type 1 diabetes mellitus: current state of knowledge.” European journal of endocrinology (2012). PMID: 22956556 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature - [55]
Zou M, Liu C. “Glucagon-like peptide-1 receptor agonists improve hepatic histology and metabolic parameters in type 2 diabetes with MASLD: a meta-analysis of randomized controlled trials.” Diabetology & metabolic syndrome (2026). PMID: 42121292 ↗
L1SR_MA_RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [56]
Guo L, Sun Z, Zhang L et al.. “HRS-7535 for Type 2 Diabetes Inadequately Controlled With Metformin: A Randomized Clinical Trial.” JAMA network open (2026). PMID: 42234428 ↗
L1RCTCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [57]
Bugbee A, Rucinsky R, Alvarez E et al.. “2026 AAHA Diabetes Management Guidelines for Cats.” Journal of the American Animal Hospital Association (2026). PMID: 42014100 ↗
L1GUIDELINECited in: Axis Physiology, Pathophysiology and Biochemical Signature - [58]
Eisa N, Barood O. “Effects of Semaglutide on Dumping Syndrome and Reactive Hypoglycemia After Bariatric Surgery: A Systematic Review and Meta-Analysis.” Obesity reviews : an official journal of the International Association for the Study of Obesity (2026). PMID: 42140745 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae - [59]
Wójcik-Sosnowska E, Tabeau A, Pawlik A et al.. “Metabolic Benefits vs. Cardiovascular Uncertainty: A Critical Review of GLP-1 Receptor Agonists in Type 1 Diabetes.” International journal of molecular sciences (2026). PMID: 42123472 ↗
L5SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae - [60]
Kanbay M, Abdel-Rahman SM, Guldan M et al.. “Clinical outcomes of glucagon-like peptide-1 receptor agonist therapy in kidney transplant recipients: a systematic review and meta-analysis.” Clinical kidney journal (2026). PMID: 42017027 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature, Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [61]
Zhu X, Wang X, Zhang P et al.. “Efficacy and safety of novel antidiabetic drugs in patients with type 2 diabetes and chronic kidney disease: a network meta-analysis.” Frontiers in endocrinology (2026). PMID: 41987895 ↗
L1SR_OBSCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [62]
Noakes TD, Prins PJ, Buga A et al.. “Carbohydrate Ingestion on Exercise Metabolism and Physical Performance.” Endocrine reviews (2026). PMID: 41562187 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature - [63]
Dynkevich Y, Rother KI, Whitford I et al.. “Tumors, IGF-2, and hypoglycemia: insights from the clinic, the laboratory, and the historical archive.” Endocrine reviews (2013). PMID: 23671155 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [64]
Gromada J, Franklin I, Wollheim CB. “Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains.” Endocrine reviews (2007). PMID: 17261637 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature - [65]
Kodl CT, Seaquist ER. “Cognitive dysfunction and diabetes mellitus.” Endocrine reviews (2008). PMID: 18436709 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [66]
Ussher JR, Drucker DJ. “Cardiovascular biology of the incretin system.” Endocrine reviews (2012). PMID: 22323472 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [67]
Marfil-Garza BA, Hefler J, Bermudez De Leon M et al.. “Progress in Translational Regulatory T Cell Therapies for Type 1 Diabetes and Islet Transplantation.” Endocrine reviews (2021). PMID: 33247733 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature - [68]
Abdul-Ghani MA, Norton L, Defronzo RA. “Role of sodium-glucose cotransporter 2 (SGLT 2) inhibitors in the treatment of type 2 diabetes.” Endocrine reviews (2011). PMID: 21606218 ↗
L5REVIEW_NARRATIVECited in: Axis Physiology, Pathophysiology and Biochemical Signature, Epidemiology, Etiology and Risk Factors - [69]
Wu CY, Shah BR, Ezekowitz JA et al.. “Effectiveness and Safety of SGLT2 Inhibitor Initiation in Sacubitril-Valsartan Users with Heart Failure: A Population-Based Cohort Study.” European heart journal. Cardiovascular pharmacotherapy (2026). PMID: 42098937 ↗
L2COHORTCited in: Axis Physiology, Pathophysiology and Biochemical Signature - [70]
Cryer PE, Axelrod L, Grossman AB et al.. “Evaluation and management of adult hypoglycemic disorders: an Endocrine Society Clinical Practice Guideline.” The Journal of clinical endocrinology and metabolism (2008). PMID: 19088155 ↗
L1GUIDELINECited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [71]
Spanakis EK, Urrutia A, Galindo RJ et al.. “Continuous Glucose Monitoring-Guided Insulin Administration in Hospitalized Patients With Diabetes: A Randomized Clinical Trial.” Diabetes care (2022). PMID: 35984478 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [72]
Rosenstock J, Cheng A, Ritzel R et al.. “More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial.” Diabetes care (2018). PMID: 30104294 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [73]
Sweeting A, Enticott J, Immanuel J et al.. “Relationship Between Early-Pregnancy Glycemia and Adverse Outcomes: Findings From the TOBOGM Study.” Diabetes care (2024). PMID: 39083673 ↗
L2RCTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [74]
Ren Q, Wang Z, Yang W et al.. “Maternal and Infant Outcomes in GCK-MODY Complicated by Pregnancy.” The Journal of clinical endocrinology and metabolism (2023). PMID: 37011183 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Prognosis, Natural History, Special Populations and Prevention - [75]
Gerstein HC, Miller ME, Byington RP et al.. “Effects of intensive glucose lowering in type 2 diabetes.” The New England journal of medicine (2008). PMID: 18539917 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [76]
Patel A, MacMahon S, Chalmers J et al.. “Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.” The New England journal of medicine (2008). PMID: 18539916 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [77]
Kahn SE, Haffner SM, Heise MA et al.. “Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy.” The New England journal of medicine (2006). PMID: 17145742 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [78]
Gunst J, Debaveye Y, Güiza F et al.. “Tight Blood-Glucose Control without Early Parenteral Nutrition in the ICU.” The New England journal of medicine (2023). PMID: 37754283 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae - [79]
Gyamfi-Bannerman C, Thom EA, Blackwell SC et al.. “Antenatal Betamethasone for Women at Risk for Late Preterm Delivery.” The New England journal of medicine (2016). PMID: 26842679 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Prognosis, Natural History, Special Populations and Prevention - [80]
Duckworth W, Abraira C, Moritz T et al.. “Glucose control and vascular complications in veterans with type 2 diabetes.” The New England journal of medicine (2008). PMID: 19092145 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [81]
Danner E, Jääskeläinen J, Niuro L et al.. “Comorbidity in Congenital Hypothyroidism-A Nationwide, Population-based Cohort Study.” The Journal of clinical endocrinology and metabolism (2023). PMID: 37279943 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae - [82]
Han E, Han KD, Lee BW et al.. “Severe Hypoglycemia Increases Dementia Risk and Related Mortality: A Nationwide, Population-based Cohort Study.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35015886 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Complications and Long-term Sequelae - [83]
Velde CD, Molnes J, Berland S et al.. “Clinical and Genetic Characteristics of Congenital Hyperinsulinism in Norway: A Nationwide Cohort Study.” The Journal of clinical endocrinology and metabolism (2025). PMID: 38963811 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [84]
Helvacioglu D, Canbaz AT, Tekmenuray-Unal A et al.. “Primary adrenal insufficiency caused by pseudo-neonatal adrenoleukodystrophy associated with biallelic ACOX1 mutations.” European journal of endocrinology (2025). PMID: 40326779 ↗
L4CASE_REPORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [85]
Umpierrez GE, Pasquel FJ. “Management of Inpatient Hyperglycemia and Diabetes in Older Adults.” Diabetes care (2017). PMID: 28325798 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [86]
Andersen A, Bagger JI, Baldassarre MPA et al.. “Acute hypoglycemia and risk of cardiac arrhythmias in insulin-treated type 2 diabetes and controls.” European journal of endocrinology (2021). PMID: 34085953 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae - [87]
Galderisi A, Kariyawasam D, Stoupa A et al.. “Glucose pattern in children with classical congenital adrenal hyperplasia: evidence from continuous glucose monitoring.” European journal of endocrinology (2023). PMID: 37952170 ↗
L4OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [88]
Battezzati A, Battezzati PM, Costantini D et al.. “Spontaneous hypoglycemia in patients with cystic fibrosis.” European journal of endocrinology (2007). PMID: 17322497 ↗
L4OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [89]
Karges B, Rosenbauer J, Holterhus PM et al.. “Hospital admission for diabetic ketoacidosis or severe hypoglycemia in 31,330 young patients with type 1 diabetes.” European journal of endocrinology (2015). PMID: 26088822 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae - [90]
Benhalima K, Van Crombrugge P, Moyson C et al.. “Risk factor screening for gestational diabetes mellitus based on the 2013 WHO criteria.” European journal of endocrinology (2019). PMID: 31120231 ↗
L2OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History, Special Populations and Prevention - [91]
Cao H, Zhou Y, Gu N et al.. “Randomized controlled trial investigating the efficacy of oral azithromycin in preventing perinatal infections in pregnant women undergoing labor induction.” International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics (2026). PMID: 42141927 ↗
L1RCTCited in: Epidemiology, Etiology and Risk Factors, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae - [92]
Cao J, Nie J, Wu D et al.. “Machine learning-based prediction models for severe Mycoplasma pneumoniae pneumonia in Chinese children: a systematic review and meta-analysis of prediction model performance.” Frontiers in public health (2026). PMID: 42318005 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Prognosis, Natural History, Special Populations and Prevention - [93]
Rusu C, Matyas M, Kramer BW et al.. “Neonatal Hypoglycemia: A Systematic Review of International and Local Clinical Guidelines with Clinical Implications.” Journal of clinical medicine (2026). PMID: 42194883 ↗
L5SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Prognosis, Natural History, Special Populations and Prevention - [94]
Coșovanu EO, Szilagyi A, Szilagyi A et al.. “Advantages of Continuous and Non-Invasive Glucose Monitoring in the Geriatric Population: A Systematic Review.” Journal of clinical medicine (2026). PMID: 42122927 ↗
L2SR_OBSCited in: Epidemiology, Etiology and Risk Factors - [95]
Phillip M, Nimri R, Bergenstal RM et al.. “Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice.” Endocrine reviews (2023). PMID: 36066457 ↗
L1OTHERCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Complications and Long-term Sequelae - [96]
Fineberg SE, Kawabata TT, Finco-Kent D et al.. “Immunological responses to exogenous insulin.” Endocrine reviews (2007). PMID: 17785428 ↗
L5REVIEW_NARRATIVECited in: Epidemiology, Etiology and Risk Factors, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [97]
Trzaski JM, Cracknell J, Herbst KW et al.. “Insulin-like growth factor-1 for the prevention or treatment of retinopathy of prematurity.” The Cochrane database of systematic reviews (2026). PMID: 41983451 ↗
L1SR_OBSCited in: Epidemiology, Etiology and Risk Factors, Severity, Staging and Risk Stratification, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [98]
Tack B, Vita D, Mbuyamba J et al.. “Non-typhoidal Salmonella co-infect and complsicate Plasmodium falciparum malaria in children under-five: A prospective cohort study on clinical presentation and outcome in Kisantu district hospital, DR Congo.” PLoS neglected tropical diseases (2026). PMID: 42341028 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [99]
Sharifi F, Abdolahpour S, Setoudeh A et al.. “Genotype-Treatment Correlations in Iranian Children with Congenital Hyperinsulinism: A Single-Center Cohort Study.” Hormone research in paediatrics (2026). PMID: 42301945 ↗
L2COHORTCited in: Epidemiology, Etiology and Risk Factors, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [100]
Hirsch IB, Bode B, Courreges JP et al.. “Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial.” Diabetes care (2012). PMID: 22933438 ↗
L1RCTCited in: Clinical Presentation - [101]
Widmer A, Zumsteg U, Szinnai G et al.. “Congenital Hyperinsulinemic Hypoglycemia With a New HADH Mutation and Pancreatic Overexpression of GLP-1 Receptors.” The Journal of clinical endocrinology and metabolism (2026). PMID: 40705962 ↗
L4CASE_REPORTCited in: Clinical Presentation - [102]
Lal RA, Bachrach LK, Hoffman AR et al.. “A Case Report of Hypoglycemia and Hypogammaglobulinemia: DAVID Syndrome in a Patient With a Novel NFKB2 Mutation.” The Journal of clinical endocrinology and metabolism (2017). PMID: 28472507 ↗
L4CASE_REPORTCited in: Clinical Presentation - [103]
Elhomsy GC, Eranki V, Albert SG et al.. “"Hyper-warburgism," a cause of asymptomatic hypoglycemia with lactic acidosis in a patient with non-Hodgkin's lymphoma.” The Journal of clinical endocrinology and metabolism (2012). PMID: 23055548 ↗
L4CASE_REPORTCited in: Clinical Presentation - [104]
Ismail D, Kapoor RR, Smith VV et al.. “The heterogeneity of focal forms of congenital hyperinsulinism.” The Journal of clinical endocrinology and metabolism (2011). PMID: 22031516 ↗
L4CASE_REPORTCited in: Clinical Presentation - [105]
De Bellis A, Colella C, Bellastella G et al.. “Late primary autoimmune hypothyroidism in a patient with postdelivery autoimmune hypopituitarism associated with antibodies to growth hormone and prolactin-secreting cells.” Thyroid : official journal of the American Thyroid Association (2013). PMID: 23286389 ↗
L4CASE_REPORTCited in: Clinical Presentation, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention - [106]
Dhanasekaran M, Mohan S, Erickson D et al.. “Diabetic Ketoacidosis in Pregnancy: Clinical Risk Factors, Presentation, and Outcomes.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35917830 ↗
L2OTHERCited in: Clinical Presentation, Acute Management and Endocrine Emergencies - [107]
Hopkins JJ, Childs AJ, Houghton JAL et al.. “Hyperinsulinemic Hypoglycemia Diagnosed in Childhood Can Be Monogenic.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36239000 ↗
L3OTHERCited in: Clinical Presentation - [108]
Zhao L, Li W, Liu L et al.. “Clinical Features and Outcome Analysis of Type B Insulin Resistance Syndrome: A Single-Center Study in China.” The Journal of clinical endocrinology and metabolism (2023). PMID: 37536271 ↗
L4OTHERCited in: Clinical Presentation - [109]
Petrelli A, Thomas NJ, Hope SV et al.. “Pathophysiology and Treatment of Type 1 Diabetes in Older Adults.” Diabetes care (2026). PMID: 42237872 ↗
L5REVIEW_NARRATIVECited in: Clinical Presentation - [110]
Lin YK, Richardson CR, Dobrin I et al.. “Beliefs Around Hypoglycemia and Their Impacts on Hypoglycemia Outcomes in Individuals with Type 1 Diabetes and High Risks for Hypoglycemia Despite Using Advanced Diabetes Technologies.” Diabetes care (2022). PMID: 35015079 ↗
L3OTHERCited in: Clinical Presentation - [111]
Redondo MJ, Libman I, Cheng P et al.. “Racial/Ethnic Minority Youth With Recent-Onset Type 1 Diabetes Have Poor Prognostic Factors.” Diabetes care (2018). PMID: 29496742 ↗
L2OTHERCited in: Clinical Presentation - [112]
Rafiq M, Flanagan SE, Patch AM et al.. “Effective treatment with oral sulfonylureas in patients with diabetes due to sulfonylurea receptor 1 (SUR1) mutations.” Diabetes care (2007). PMID: 18025408 ↗
L2OTHERCited in: Clinical Presentation - [113]
Lim DBN, Bryce J, Ali SR et al.. “Contemporary global management of 21-hydroxylase deficiency congenital adrenal hyperplasia in early infancy: a multi-national registry study.” European journal of endocrinology (2026). PMID: 41531283 ↗
L2OTHERCited in: Clinical Presentation, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [114]
Boodhansingh KE, Yang Z, Li C et al.. “Localized islet nuclear enlargement hyperinsulinism (LINE-HI) due to ABCC8 and GCK mosaic mutations.” European journal of endocrinology (2022). PMID: 35674212 ↗
L4OTHERCited in: Clinical Presentation - [115]
van Oldenmark BO, van Steenis A, van der Aa NE et al.. “Perinatal arterial ischemic stroke (PAIS) and neonatal cerebral sinovenous thrombosis (CSVT) in the preterm neonate: a systematic review.” Pediatric research (2026). PMID: 41680509 ↗
L1SR_OBSCited in: Clinical Presentation - [116]
Sinclair JC, Bottino M, Cowett RM. “Interventions for prevention of neonatal hyperglycemia in very low birth weight infants.” The Cochrane database of systematic reviews (2011). PMID: 21975772 ↗
L1SR_OBSCited in: Clinical Presentation, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [117]
Sinclair JC, Bottino M, Cowett RM. “Interventions for prevention of neonatal hyperglycemia in very low birth weight infants.” The Cochrane database of systematic reviews (2009). PMID: 19588439 ↗
L1SR_OBSCited in: Clinical Presentation, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [118]
Jiang L, Shao H, Wang X et al.. “Early Pregnancy Triglyceride to HDL-C Ratio Predicts Gestational Diabetes Mellitus and Neonatal Hypoglycemia: A Retrospective Cohort Study.” Diabetes, metabolic syndrome and obesity : targets and therapy (2026). PMID: 42004934 ↗
L2COHORTCited in: Clinical Presentation - [119]
Ngo EMT, Rowe JM, Chillon TS et al.. “Type B insulin resistance with glycemic extremes: a case report and literature review.” Frontiers in endocrinology (2026). PMID: 42255432 ↗
L4CASE_REPORTCited in: Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [120]
Kraft BD, Matuszak S. “Angioedema After Accidental Semaglutide Dosing Error: A Case Report.” Journal of clinical medicine (2026). PMID: 42194666 ↗
L4CASE_REPORTCited in: Clinical Presentation, Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [121]
Sanders VR, Lord K, Sigal W et al.. “Double Trouble: When Focal and Diffuse Hyperinsulinism Occur Simultaneously.” Hormone research in paediatrics (2026). PMID: 41795819 ↗
L4CASE_REPORTCited in: Clinical Presentation - [122]
Karkalemis K, Papadopoulou-Marketou N, Kalampokas E et al.. “Ovarian stimulation toward oocyte cryopreservation for fertility preservation in a patient with Hirata syndrome: a clinical challenge in assisted reproduction.” Archives of gynecology and obstetrics (2026). PMID: 41652049 ↗
L4CASE_REPORTCited in: Clinical Presentation - [123]
McCall AL, Lieb DC, Gianchandani R et al.. “Management of Individuals With Diabetes at High Risk for Hypoglycemia: An Endocrine Society Clinical Practice Guideline.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36477488 ↗
L1GUIDELINECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [124]
Seisa MO, Saadi S, Nayfeh T et al.. “A Systematic Review Supporting the Endocrine Society Clinical Practice Guideline for the Management of Hyperglycemia in Adults Hospitalized for Noncritical Illness or Undergoing Elective Surgical Procedures.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35690929 ↗
L1GUIDELINECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [125]
Brar PC, Heksch R, Cossen K et al.. “Management and Appropriate Use of Diazoxide in Infants and Children with Hyperinsulinism.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32810255 ↗
L5GUIDELINECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Severity, Staging and Risk Stratification, Prognosis, Natural History, Special Populations and Prevention - [126]
Uhl S, Choure A, Rouse B et al.. “Effectiveness of Continuous Glucose Monitoring on Metrics of Glycemic Control in Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.” The Journal of clinical endocrinology and metabolism (2024). PMID: 37987208 ↗
L1SR_MA_RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies - [127]
Luo Y, Wang J, Sun L et al.. “Isocaloric-restricted Mediterranean Diet and Chinese Diets High or Low in Plants in Adults With Prediabetes.” The Journal of clinical endocrinology and metabolism (2022). PMID: 35579171 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [128]
Obermayer A, Tripolt NJ, Pferschy PN et al.. “Efficacy and Safety of Intermittent Fasting in People With Insulin-Treated Type 2 Diabetes (INTERFAST-2)-A Randomized Controlled Trial.” Diabetes care (2023). PMID: 36508320 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [129]
Yew TW, Chi C, Chan SY et al.. “A Randomized Controlled Trial to Evaluate the Effects of a Smartphone Application-Based Lifestyle Coaching Program on Gestational Weight Gain, Glycemic Control, and Maternal and Neonatal Outcomes in Women With Gestational Diabetes Mellitus: The SMART-GDM Study.” Diabetes care (2020). PMID: 33184151 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [130]
. “A Randomized Clinical Trial Assessing Continuous Glucose Monitoring (CGM) Use With Standardized Education With or Without a Family Behavioral Intervention Compared With Fingerstick Blood Glucose Monitoring in Very Young Children With Type 1 Diabetes.” Diabetes care (2020). PMID: 33334807 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [131]
Hirsch IB, Draznin B, Buse JB et al.. “Results From a Randomized Trial of Intensive Glucose Management Using CGM Versus Usual Care in Hospitalized Adults With Type 2 Diabetes: The TIGHT Study.” Diabetes care (2025). PMID: 39571106 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies - [132]
Bajaj HS, Ásbjörnsdóttir B, Carstensen L et al.. “Continuous Glucose Monitoring-Based Metrics and Hypoglycemia Duration in Insulin-Experienced Individuals With Long-standing Type 2 Diabetes Switched From a Daily Basal Insulin to Once-Weekly Insulin Icodec: Post Hoc Analysis of ONWARDS 2 and ONWARDS 4.” Diabetes care (2024). PMID: 38380954 ↗
L2RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [133]
Kudva YC, Raghinaru D, Lum JW et al.. “A Randomized Trial of Automated Insulin Delivery in Type 2 Diabetes.” The New England journal of medicine (2025). PMID: 40105270 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [134]
Wadwa RP, Reed ZW, Buckingham BA et al.. “Trial of Hybrid Closed-Loop Control in Young Children with Type 1 Diabetes.” The New England journal of medicine (2023). PMID: 36920756 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies - [135]
Landon MB, Spong CY, Thom E et al.. “A multicenter, randomized trial of treatment for mild gestational diabetes.” The New England journal of medicine (2009). PMID: 19797280 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History, Special Populations and Prevention - [136]
Russell SJ, Beck RW, Damiano ER et al.. “Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes.” The New England journal of medicine (2022). PMID: 36170500 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies - [137]
Leelarathna L, Evans ML, Neupane S et al.. “Intermittently Scanned Continuous Glucose Monitoring for Type 1 Diabetes.” The New England journal of medicine (2022). PMID: 36198143 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [138]
Boughton CK, Allen JM, Ware J et al.. “Closed-Loop Therapy and Preservation of C-Peptide Secretion in Type 1 Diabetes.” The New England journal of medicine (2022). PMID: 36069870 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [139]
Ludvigsson J, Krisky D, Casas R et al.. “GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus.” The New England journal of medicine (2012). PMID: 22296077 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [140]
Shah VN, DuBose SN, Li Z et al.. “Continuous Glucose Monitoring Profiles in Healthy Nondiabetic Participants: A Multicenter Prospective Study.” The Journal of clinical endocrinology and metabolism (2019). PMID: 31127824 ↗
L2COHORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [141]
Oskarsson P, Antuna R, Geelhoed-Duijvestijn P et al.. “Impact of flash glucose monitoring on hypoglycaemia in adults with type 1 diabetes managed with multiple daily injection therapy: a pre-specified subgroup analysis of the IMPACT randomised controlled trial.” Diabetologia (2017). PMID: 29273897 ↗
L1RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [142]
Morioka T, Ohba K, Morita H et al.. “Non-islet cell tumor-induced hypoglycemia associated with macronodular pulmonary metastases from poorly differentiated thyroid carcinoma.” Thyroid : official journal of the American Thyroid Association (2013). PMID: 23697382 ↗
L4CASE_REPORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [143]
Di Candia S, Gessi A, Pepe G et al.. “Identification of a diffuse form of hyperinsulinemic hypoglycemia by 18-fluoro-L-3,4 dihydroxyphenylalanine positron emission tomography/CT in a patient carrying a novel mutation of the HADH gene.” European journal of endocrinology (2009). PMID: 19318379 ↗
L4CASE_REPORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Prognosis, Natural History, Special Populations and Prevention - [144]
Nwokolo M, Hovorka R. “The Artificial Pancreas and Type 1 Diabetes.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36734145 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [145]
Danne T, Nimri R, Battelino T et al.. “International Consensus on Use of Continuous Glucose Monitoring.” Diabetes care (2017). PMID: 29162583 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae - [146]
Holt RIG, DeVries JH, Hess-Fischl A et al.. “The Management of Type 1 Diabetes in Adults. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).” Diabetes care (2021). PMID: 34593612 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Complications and Long-term Sequelae - [147]
Flanagan SE, Kapoor RR, Mali G et al.. “Diazoxide-responsive hyperinsulinemic hypoglycemia caused by HNF4A gene mutations.” European journal of endocrinology (2010). PMID: 20164212 ↗
L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention - [148]
Bonnet-Serrano F, Devin-Genteuil C, Thomeret L et al.. “C-peptide level concomitant with hypoglycemia gives better performances than insulin for the diagnosis of endogenous hyperinsulinism: a single-center study of 159 fasting trials.” European journal of endocrinology (2023). PMID: 36756737 ↗
L3OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [149]
Martínez R, Fernández-Ramos C, Vela A et al.. “Clinical and genetic characterization of congenital hyperinsulinism in Spain.” European journal of endocrinology (2016). PMID: 27188453 ↗
L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [150]
Sun Q, Zhao G. “The Efficacy and Safety of Teplizumab in the Treatment of Stage 3 Type 1 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.” Diabetes, metabolic syndrome and obesity : targets and therapy (2026). PMID: 42221148 ↗
L1SR_MA_RCTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies - [151]
Siegelaar SE, Holleman F, Hoekstra JB et al.. “Glucose variability; does it matter?” Endocrine reviews (2009). PMID: 19966012 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [152]
Finken MJJ, van der Steen M, Smeets CCJ et al.. “Children Born Small for Gestational Age: Differential Diagnosis, Molecular Genetic Evaluation, and Implications.” Endocrine reviews (2018). PMID: 29982551 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [153]
Bruschettini M, Badura A, Romantsik O. “Stem cell-based interventions for the treatment of stroke in newborn infants.” The Cochrane database of systematic reviews (2023). PMID: 37994736 ↗
L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [154]
Onady GM, Stolfi A. “Drug treatments for managing cystic fibrosis-related diabetes.” The Cochrane database of systematic reviews (2020). PMID: 33075159 ↗
L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [155]
Onady GM, Stolfi A. “Insulin and oral agents for managing cystic fibrosis-related diabetes.” The Cochrane database of systematic reviews (2016). PMID: 27087121 ↗
L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [156]
Onady GM, Stolfi A. “Insulin and oral agents for managing cystic fibrosis-related diabetes.” The Cochrane database of systematic reviews (2013). PMID: 23893261 ↗
L1SR_OBSCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [157]
Herranz-Antolín S, Gómez-Peralta F, Yongjin X et al.. “Increased Glycation Ratio and Risk of Complications in Latent Autoimmune Diabetes in Adults Compared With Type 1 Diabetes Onset before 30 Years: A Cohort Study.” Diabetes technology & therapeutics (2026). PMID: 42210521 ↗
L4COHORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [158]
Piccolo C, de Candia S, Natalicchio A et al.. “Phenylketonuria and type 1 diabetes: a clinical and nutritional challenge in a young adult-a case report.” Acta diabetologica (2026). PMID: 42319439 ↗
L4CASE_REPORTCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [159]
Ahmed F, Khan S, Gohar N et al.. “Clinical Outcomes of GLP-1 Receptor Agonist and SGLT2 Inhibitor Combination Therapy in Heart Failure: A Real-World Propensity-Matched TriNetX Analysis.” Biomedicines (2026). PMID: 42351796 ↗
L2OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [160]
Khalafalla HE, Albasheer O, Elfaki FA et al.. “Diabetes-related stigma among individuals with type 1 diabetes in Jazan, Saudi Arabia: sociodemographic and clinical correlates.” Frontiers in endocrinology (2026). PMID: 42339084 ↗
L4OTHERCited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [161]
Forțofoiu D, Sacerdoțianu VM, Șerban RE et al.. “Paraneoplastic Endocrine Changes in Gastrointestinal Tumors: A Clinical and Mechanistic Review.” International journal of molecular sciences (2026). PMID: 42278207 ↗
L5REVIEW_NARRATIVECited in: Diagnosis and Workup: Paired Hormones, Dynamic Testing and Localization - [162]
Klonoff DC, Buckingham B, Christiansen JS et al.. “Continuous glucose monitoring: an Endocrine Society Clinical Practice Guideline.” The Journal of clinical endocrinology and metabolism (2011). PMID: 21976745 ↗
L1GUIDELINECited in: Severity, Staging and Risk Stratification - [163]
Frias JP, Choi J, Rosenstock J et al.. “Efficacy and Safety of Once-Weekly Efpeglenatide Monotherapy Versus Placebo in Type 2 Diabetes: The AMPLITUDE-M Randomized Controlled Trial.” Diabetes care (2022). PMID: 35671039 ↗
L1RCTCited in: Severity, Staging and Risk Stratification - [164]
Montaser E, Williams C, Shah VN. “Assessing Time Below Range as a Predictor of Severe Hypoglycemia: Insights From Six Clinical Trials.” Diabetes care (2026). PMID: 41529164 ↗
L2TRIAL_NONRANDOMCited in: Severity, Staging and Risk Stratification - [165]
Torres Roldan VD, Urtecho M, Nayfeh T et al.. “A Systematic Review Supporting the Endocrine Society Guidelines: Management of Diabetes and High Risk of Hypoglycemia.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36477885 ↗
L1SR_OBSCited in: Severity, Staging and Risk Stratification - [166]
Lundemose SB, Ranjan AG, Nørgaard O et al.. “Low-Dose Glucagon to Prevent and Treat Exercise-Associated Hypoglycemia in Individuals With Type 1 Diabetes: A Systematic Review and Meta-analysis.” Diabetes care (2025). PMID: 40834249 ↗
L1SR_OBSCited in: Severity, Staging and Risk Stratification - [167]
Rosenstock J, Bajaj HS, Janež A et al.. “Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment.” The New England journal of medicine (2020). PMID: 32960514 ↗
L1RCTCited in: Severity, Staging and Risk Stratification - [168]
Agus MS, Wypij D, Hirshberg EL et al.. “Tight Glycemic Control in Critically Ill Children.” The New England journal of medicine (2017). PMID: 28118549 ↗
L1RCTCited in: Severity, Staging and Risk Stratification - [169]
Pasquel FJ, Tsegka K, Wang H et al.. “Clinical Outcomes in Patients With Isolated or Combined Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic State: A Retrospective, Hospital-Based Cohort Study.” Diabetes care (2019). PMID: 31704689 ↗
L2COHORTCited in: Severity, Staging and Risk Stratification, Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae - [170]
Lord K, De León DD. “Approach to the Neonate With Hypoglycemia.” The Journal of clinical endocrinology and metabolism (2024). PMID: 38629854 ↗
L5CASE_REPORTCited in: Severity, Staging and Risk Stratification, Prognosis, Natural History, Special Populations and Prevention - [171]
. “6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes-2025.” Diabetes care (2025). PMID: 39651981 ↗
L1REVIEW_NARRATIVECited in: Severity, Staging and Risk Stratification - [172]
. “6. Glycemic Goals and Hypoglycemia: Standards of Care in Diabetes-2024.” Diabetes care (2024). PMID: 38078586 ↗
L1REVIEW_NARRATIVECited in: Severity, Staging and Risk Stratification - [173]
Ji L, Cheng Z, Ma J et al.. “HTD1801 in Combination with Metformin for Type 2 Diabetes.” NEJM evidence (2026). PMID: 42251702 ↗
L1RCTCited in: Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [174]
Li Y, Chen J, Gao Y et al.. “Comparative Safety of SGLT2 Versus DPP4 Inhibitors in Patients with Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials.” Diabetes therapy : research, treatment and education of diabetes and related disorders (2026). PMID: 41678006 ↗
L1SR_MA_RCTCited in: Severity, Staging and Risk Stratification - [175]
Albazee E, AlOtaibi A, Alsaffar H et al.. “Microneedling with Topical Insulin Versus Microneedling with Platelet-rich Plasma for Post-Acne Scars: A Systematic Review and Meta-Analysis with Trial Sequential Analysis.” Aesthetic plastic surgery (2026). PMID: 42324392 ↗
L1SR_OBSCited in: Severity, Staging and Risk Stratification, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [176]
Liu C, Mujahid O, Beneyto A et al.. “Sex differences in glycemic outcomes: a systematic review and meta-analysis of diabetes treatments.” BMJ open diabetes research & care (2026). PMID: 42020119 ↗
L1SR_OBSCited in: Severity, Staging and Risk Stratification - [177]
Gilbert BW, Turpin BB, Murray DS et al.. “The Evaluation of Early Basal Insulin in Diabetic Ketoacidosis: A Systematic Review and Meta-Analysis.” Diabetes/metabolism research and reviews (2026). PMID: 41865288 ↗
L1SR_OBSCited in: Severity, Staging and Risk Stratification - [178]
Zhou Z, Liu C, Xu Q et al.. “Effects of glucose-containing dialysates for patients with maintenance hemodialysis: a systematic review, pairwise and network meta-analysis.” Systematic reviews (2026). PMID: 41742316 ↗
L1SR_OBSCited in: Severity, Staging and Risk Stratification - [179]
Umpierrez GE, Smiley D, Zisman A et al.. “Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial).” Diabetes care (2007). PMID: 17513708 ↗
L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [180]
Rosenstock J, Marquard J, Laffel LM et al.. “Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.” Diabetes care (2018). PMID: 30287422 ↗
L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [181]
Lauritzen ES, Voss T, Kampmann U et al.. “Circulating acylghrelin levels are suppressed by insulin and increase in response to hypoglycemia in healthy adult volunteers.” European journal of endocrinology (2015). PMID: 25599708 ↗
L1RCTCited in: Acute Management and Endocrine Emergencies - [182]
Olsen MT, Liarakos AL, Wilmot EG et al.. “Implementation Strategies for Inpatient Continuous Glucose Monitoring-based Diabetes Management: A Systematic Review.” The Journal of clinical endocrinology and metabolism (2025). PMID: 39918053 ↗
L2SR_OBSCited in: Acute Management and Endocrine Emergencies - [183]
Finfer S, Chittock DR, Su SY et al.. “Intensive versus conventional glucose control in critically ill patients.” The New England journal of medicine (2009). PMID: 19318384 ↗
L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [184]
Bhatt DL, Szarek M, Steg PG et al.. “Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.” The New England journal of medicine (2020). PMID: 33200892 ↗
L1RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [185]
Burnside MJ, Lewis DM, Crocket HR et al.. “Open-Source Automated Insulin Delivery in Type 1 Diabetes.” The New England journal of medicine (2022). PMID: 36069869 ↗
L1RCTCited in: Acute Management and Endocrine Emergencies - [186]
Taylor SI, Blau JE, Rother KI. “SGLT2 Inhibitors May Predispose to Ketoacidosis.” The Journal of clinical endocrinology and metabolism (2015). PMID: 26086329 ↗
L5REVIEW_NARRATIVECited in: Acute Management and Endocrine Emergencies - [187]
Prahalad P, Zaharieva D, Maahs DM. “Diabetes technology: an update.” The Journal of clinical endocrinology and metabolism (2026). PMID: 41973910 ↗
L5REVIEW_NARRATIVECited in: Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae - [188]
Prinz N, Konrad K, Brack C et al.. “Diabetes care in pediatric refugees from Africa or Middle East: experiences from Germany and Austria based on real-world data from the DPV registry.” European journal of endocrinology (2019). PMID: 31075760 ↗
L2OTHERCited in: Acute Management and Endocrine Emergencies, Prognosis, Natural History, Special Populations and Prevention - [189]
Odenwald B, Nennstiel-Ratzel U, Dörr HG et al.. “Children with classic congenital adrenal hyperplasia experience salt loss and hypoglycemia: evaluation of adrenal crises during the first 6 years of life.” European journal of endocrinology (2015). PMID: 26563979 ↗
L4OTHERCited in: Acute Management and Endocrine Emergencies - [190]
Donovan LE, Lemieux P, Yamamoto JM et al.. “Intrapartum and Early Postpartum Use of Automated Insulin Delivery in Type 1 Diabetes: A Prespecified Analysis of the CIRCUIT Randomized Controlled Trial.” Diabetes care (2026). PMID: 42201836 ↗
L1RCTCited in: Acute Management and Endocrine Emergencies, Prognosis, Natural History, Special Populations and Prevention - [191]
Olsen MT, Liarakos AL, Wilmot EG et al.. “Automated Insulin Delivery Systems in Hospitals: A Systematic Review with Meta-Analysis.” Diabetes technology & therapeutics (2026). PMID: 42338280 ↗
L1SR_OBSCited in: Acute Management and Endocrine Emergencies, Complications and Long-term Sequelae - [192]
Felippe CA, Ruiz SDSC, de Souza RF et al.. “Antenatal Corticosteroid Use in Twin Pregnancies: A Systematic Review and Meta-analysis.” Obstetrics and gynecology (2026). PMID: 42241699 ↗
L1SR_OBSCited in: Acute Management and Endocrine Emergencies, Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [193]
Rickels MR, Robertson RP. “Pancreatic Islet Transplantation in Humans: Recent Progress and Future Directions.” Endocrine reviews (2019). PMID: 30541144 ↗
L5REVIEW_NARRATIVECited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [194]
Ogolo D, Achebe D, Ani F et al.. “The impact of timing, dosage, and duration of high-dose methylprednisolone on neurological recovery and complications in acute spinal cord injury: A systematic review and meta-analysis of randomized controlled trials.” The journal of spinal cord medicine (2026). PMID: 42240612 ↗
L1SR_MA_RCTCited in: Acute Management and Endocrine Emergencies, Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [195]
Wilson LM, Herzig SJ, Marcantonio ER et al.. “Management of Diabetes and Hyperglycemia in the Hospital: A Systematic Review of Clinical Practice Guidelines.” Diabetes care (2025). PMID: 40117466 ↗
L1GUIDELINECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [196]
Craig CM, Lawler HM, Lee CJE et al.. “PREVENT: A Randomized, Placebo-controlled Crossover Trial of Avexitide for Treatment of Postbariatric Hypoglycemia.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33616643 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [197]
Lingvay I, Bache JK, Desouza CV et al.. “Efficacy and Hypoglycemia Profile of Once-weekly Insulin Icodec vs Once-daily Comparators Across Demographic Subgroups.” The Journal of clinical endocrinology and metabolism (2025). PMID: 40102962 ↗
L2RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [198]
Celli A, Barnouin Y, Jiang B et al.. “Lifestyle Intervention Strategy to Treat Diabetes in Older Adults: A Randomized Controlled Trial.” Diabetes care (2022). PMID: 35880801 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [199]
Park J, Ntelis S, Yunasan E et al.. “Glucagon-Like Peptide 1 Analogues as Adjunctive Therapy for Patients With Type 1 Diabetes: An Updated Systematic Review and Meta-analysis.” The Journal of clinical endocrinology and metabolism (2023). PMID: 37561012 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [200]
Vega-Beyhart A, Biagetti B, Marazuela M et al.. “Efficacy and Safety of Pasireotide in Insulinoma-Associated Hypoglycemia.” The Journal of clinical endocrinology and metabolism (2025). PMID: 40165498 ↗
L2SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [201]
McMurray JJV, Solomon SD, Inzucchi SE et al.. “Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.” The New England journal of medicine (2019). PMID: 31535829 ↗
L1RCTCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [202]
Kittah NE, Vella A. “MANAGEMENT OF ENDOCRINE DISEASE: Pathogenesis and management of hypoglycemia.” European journal of endocrinology (2017). PMID: 28381450 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [203]
Xie L, Lu W, Yu J et al.. “Regulation of insulin expression and release in gene and cell therapy of insulin-deficient diabetes.” European journal of endocrinology (2025). PMID: 41250859 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [204]
Abrahamsson N, Edén Engström B, Sundbom M et al.. “Hypoglycemia in everyday life after gastric bypass and duodenal switch.” European journal of endocrinology (2015). PMID: 25899582 ↗
L3OTHERCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [205]
Raptis D, Chiotis S, Papamichalis T et al.. “Efficacy and safety of once-weekly basal insulin analogs versus daily basal insulin analogs in adults with type 2 diabetes: a systematic review and meta-analysis.” Current diabetes reports (2026). PMID: 42277362 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [206]
Gordillo-Rosas L, Cajachagua-Pucuhuaranga CL, Cruz-Venegas JS et al.. “Automated insulin delivery in type 2 diabetes: a meta-analysis of randomized trials protocol.” Systematic reviews (2026). PMID: 42265738 ↗
L5SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [207]
Sirimaturos M, Honarmand K, Long MT et al.. “Comparison of Intensive Versus Conventional Glycemic Control Targets: An Updated Systematic Review and Meta-Analysis of the 2024 Society of Critical Care Medicine Guidelines on Glycemic Control for Critically Ill Adults.” Critical care medicine (2026). PMID: 42262517 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [208]
Rosenstock J, Juneja R, Beals JM et al.. “The Basis for Weekly Insulin Therapy: Evolving Evidence With Insulin Icodec and Insulin Efsitora Alfa.” Endocrine reviews (2024). PMID: 38224978 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [209]
Galindo RJ, Beck RW, Scioscia MF et al.. “Glycemic Monitoring and Management in Advanced Chronic Kidney Disease.” Endocrine reviews (2020). PMID: 32455432 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [210]
Stanley S, Moheet A, Seaquist ER. “Central Mechanisms of Glucose Sensing and Counterregulation in Defense of Hypoglycemia.” Endocrine reviews (2019). PMID: 30689785 ↗
L5REVIEW_NARRATIVECited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [211]
Narula N, Dhillon A, Zhang D et al.. “Enteral nutritional therapy for induction of remission in Crohn's disease.” The Cochrane database of systematic reviews (2018). PMID: 29607496 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Prognosis, Natural History, Special Populations and Prevention - [212]
Fan L, Xu J, Wang T et al.. “Sulfonylurea drugs for people with severe hemispheric ischemic stroke.” The Cochrane database of systematic reviews (2025). PMID: 40066941 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [213]
Galderisi A, Bruschettini M, Russo C et al.. “Continuous glucose monitoring for the prevention of morbidity and mortality in preterm infants.” The Cochrane database of systematic reviews (2020). PMID: 33348448 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae, Prognosis, Natural History, Special Populations and Prevention - [214]
Ozek E, Soll R, Schimmel MS. “Partial exchange transfusion to prevent neurodevelopmental disability in infants with polycythemia.” The Cochrane database of systematic reviews (2010). PMID: 20091569 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive), Complications and Long-term Sequelae - [215]
Ma X, Mo Z, Chen Y et al.. “Clinical Trial for Safety of Porcine Islet Xenotransplantation From PERV-C Free DPF Donor Piglets in Patients With Type 1 Diabetes.” Xenotransplantation (2026). PMID: 42305014 ↗
L2TRIAL_NONRANDOMCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [216]
Borooghani H, Arabi M, Kazemi Jahromi M. “Efficacy and Safety of Oral Antidiabetic Drugs in People with Diabetes and Chronic Kidney Disease: A Systematic Review.” Iranian journal of kidney diseases (2025). PMID: 42234904 ↗
L1SR_OBSCited in: Long-term Management: Treat-to-Target (Replacement, Suppression, Definitive) - [217]
D'Anna R, Scilipoti A, Giordano D et al.. “myo-Inositol supplementation and onset of gestational diabetes mellitus in pregnant women with a family history of type 2 diabetes: a prospective, randomized, placebo-controlled study.” Diabetes care (2013). PMID: 23340885 ↗
L1RCTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [218]
David O, Barash G, Agur R et al.. “Multiple Endocrine Deficiencies are Common in Hypoparathyroidism-Retardation-Dysmorphism Syndrome.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33150438 ↗
L4TRIAL_NONRANDOMCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [219]
White WB, Cannon CP, Heller SR et al.. “Alogliptin after acute coronary syndrome in patients with type 2 diabetes.” The New England journal of medicine (2013). PMID: 23992602 ↗
L1RCTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [220]
Calder GL, Ward GM, Sachithanandan N et al.. “Insulin Autoimmune Syndrome: A Case of Clopidogrel-induced Autoimmune Hypoglycemia.” The Journal of clinical endocrinology and metabolism (2020). PMID: 32182368 ↗
L4CASE_REPORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [221]
Liu Y, Ping F, Yu J et al.. “Hypoglycemia Caused by Exogenous Insulin Antibody Syndrome: A Large Single-Center Case Series From China.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36219196 ↗
L4CASE_REPORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects, Prognosis, Natural History, Special Populations and Prevention - [222]
Arya VB, Flanagan SE, Schober E et al.. “Activating AKT2 mutation: hypoinsulinemic hypoketotic hypoglycemia.” The Journal of clinical endocrinology and metabolism (2013). PMID: 24285683 ↗
L4CASE_REPORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [223]
Myngheer N, Allegaert K, Hattersley A et al.. “Fetal macrosomia and neonatal hyperinsulinemic hypoglycemia associated with transplacental transfer of sulfonylurea in a mother with KCNJ11-related neonatal diabetes.” Diabetes care (2014). PMID: 25231897 ↗
L4CASE_REPORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [224]
Rohayem J, Ehlers C, Wiedemann B et al.. “Diabetes and neurodegeneration in Wolfram syndrome: a multicenter study of phenotype and genotype.” Diabetes care (2011). PMID: 21602428 ↗
L3OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [225]
Gupta K, Rajagopal R, King F et al.. “Complications of Antenatal Corticosteroids in Infants Born by Early Term Scheduled Cesarean Section.” Diabetes care (2020). PMID: 31974101 ↗
L3OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [226]
Dagogo-Jack S. “Philip E. Cryer, MD: Seminal Contributions to the Understanding of Hypoglycemia and Glucose Counterregulation and the Discovery of HAAF (Cryer Syndrome).” Diabetes care (2015). PMID: 26604275 ↗
L5OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [227]
Al Mutair AN, Brusgaard K, Bin-Abbas B et al.. “Heterogeneity in phenotype of usher-congenital hyperinsulinism syndrome: hearing loss, retinitis pigmentosa, and hyperinsulinemic hypoglycemia ranging from severe to mild with conversion to diabetes.” Diabetes care (2012). PMID: 23150283 ↗
L4OTHERCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [228]
Li W, Wang T, Zhang J. “Antenatal corticosteroid administration-to-delivery intervals and neonatal outcomes in late preterm labor: a historical cohort study.” BMC pregnancy and childbirth (2026). PMID: 41872805 ↗
L3COHORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [229]
Tang H, Chen Z, Wang S et al.. “Predictive value of three insulin resistance surrogate indices for symptomatic hypoglycemia risk in hospitalized patients with type 2 diabetes: a retrospective cohort study.” BMC endocrine disorders (2026). PMID: 41851856 ↗
L3COHORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [230]
Chen Y, Song H, Yang M. “Association between glycemic variability and composite adverse neonatal outcomes in patients with gestational diabetes mellitus: a retrospective study.” The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians (2026). PMID: 42108378 ↗
L3COHORTCited in: Multiglandular Syndromes, Genetic Context and Co-Axis Effects - [231]
Shalimova A, Graff B, Gąsecki D et al.. “Cognitive Dysfunction in Type 1 Diabetes Mellitus.” The Journal of clinical endocrinology and metabolism (2019). PMID: 30657922 ↗
L5REVIEW_NARRATIVECited in: Complications and Long-term Sequelae - [232]
Bernard V, Lombard-Bohas C, Taquet MC et al.. “Efficacy of everolimus in patients with metastatic insulinoma and refractory hypoglycemia.” European journal of endocrinology (2013). PMID: 23392213 ↗
L4OTHERCited in: Complications and Long-term Sequelae - [233]
Hadjadj S, Ragot S, Durocher L et al.. “Impact of high intensity physical activity compared to routine counseling on renal function decline in patients with type 2 diabetes at high risk for kidney disease - the ACTIDIANE randomized controlled trial.” Diabetes & metabolism (2026). PMID: 42177980 ↗
L1RCTCited in: Complications and Long-term Sequelae - [234]
Lal RA, Ekhlaspour L, Hood K et al.. “Realizing a Closed-Loop (Artificial Pancreas) System for the Treatment of Type 1 Diabetes.” Endocrine reviews (2019). PMID: 31276160 ↗
L5REVIEW_NARRATIVECited in: Complications and Long-term Sequelae - [235]
Kuo CH, Lin MW, Chen SC et al.. “The Effect of Midpregnancy Screening for Gestational Diabetes Mellitus on Pregnancy Outcomes: The TESGO Randomized Controlled Trial.” Diabetes care (2026). PMID: 40986699 ↗
L1RCTCited in: Prognosis, Natural History, Special Populations and Prevention - [236]
Buschur EO, Polsky S. “Type 1 Diabetes: Management in Women From Preconception to Postpartum.” The Journal of clinical endocrinology and metabolism (2021). PMID: 33331893 ↗
L5SR_OBSCited in: Prognosis, Natural History, Special Populations and Prevention - [237]
Gaudieri PA, Chen R, Greer TF et al.. “Cognitive function in children with type 1 diabetes: a meta-analysis.” Diabetes care (2008). PMID: 18753668 ↗
L1SR_OBSCited in: Prognosis, Natural History, Special Populations and Prevention - [238]
Léauté-Labrèze C, Hoeger P, Mazereeuw-Hautier J et al.. “A randomized, controlled trial of oral propranolol in infantile hemangioma.” The New England journal of medicine (2015). PMID: 25693013 ↗
L1RCTCited in: Prognosis, Natural History, Special Populations and Prevention - [239]
Beardsall K, Vanhaesebrouck S, Ogilvy-Stuart AL et al.. “Early insulin therapy in very-low-birth-weight infants.” The New England journal of medicine (2008). PMID: 18971490 ↗
L1RCTCited in: Prognosis, Natural History, Special Populations and Prevention - [240]
Brunkhorst FM, Engel C, Bloos F et al.. “Intensive insulin therapy and pentastarch resuscitation in severe sepsis.” The New England journal of medicine (2008). PMID: 18184958 ↗
L1RCTCited in: Prognosis, Natural History, Special Populations and Prevention - [241]
Macrae D, Grieve R, Allen E et al.. “A randomized trial of hyperglycemic control in pediatric intensive care.” The New England journal of medicine (2014). PMID: 24401049 ↗
L1RCTCited in: Prognosis, Natural History, Special Populations and Prevention - [242]
Stewart ZA, Wilinska ME, Hartnell S et al.. “Closed-Loop Insulin Delivery during Pregnancy in Women with Type 1 Diabetes.” The New England journal of medicine (2016). PMID: 27532830 ↗
L1RCTCited in: Prognosis, Natural History, Special Populations and Prevention - [243]
Le Quan Sang KH, Arnoux JB, Mamoune A et al.. “Successful treatment of congenital hyperinsulinism with long-acting release octreotide.” European journal of endocrinology (2011). PMID: 22048969 ↗
L4TRIAL_NONRANDOMCited in: Prognosis, Natural History, Special Populations and Prevention - [244]
Cox DJ, Gonder-Frederick L, Ritterband L et al.. “Prediction of severe hypoglycemia.” Diabetes care (2007). PMID: 17363757 ↗
L2OTHERCited in: Prognosis, Natural History, Special Populations and Prevention - [245]
Yland JJ, Huybrechts KF, Wesselink AK et al.. “Perinatal Outcomes Associated With Metformin Use During Pregnancy in Women With Pregestational Type 2 Diabetes Mellitus.” Diabetes care (2024). PMID: 39042587 ↗
L2OTHERCited in: Prognosis, Natural History, Special Populations and Prevention - [246]
McGrath RT, Glastras SJ, Hocking SL et al.. “Large-for-Gestational-Age Neonates in Type 1 Diabetes and Pregnancy: Contribution of Factors Beyond Hyperglycemia.” Diabetes care (2018). PMID: 30030258 ↗
L5REVIEW_NARRATIVECited in: Prognosis, Natural History, Special Populations and Prevention - [247]
Immanuel J, Simmons D. “A Perspective on the Accuracy of Blood Glucose Meters During Pregnancy.” Diabetes care (2018). PMID: 30237233 ↗
L5REVIEW_NARRATIVECited in: Prognosis, Natural History, Special Populations and Prevention - [248]
Hauffa BP, Lehmann N, Bettendorf M et al.. “Central laboratory reassessment of IGF-I, IGF-binding protein-3, and GH serum concentrations measured at local treatment centers in growth-impaired children: implications for the agreement between outpatient screening and the results of somatotropic axis functional testing.” European journal of endocrinology (2007). PMID: 17984239 ↗
L4OTHERCited in: Prognosis, Natural History, Special Populations and Prevention - [249]
Moser O, Becker U, van den Boom L et al.. “[Automated insulin delivery (AID) systems, physical activity and sports in type 1 diabetes mellitus: joint guidelines of the DDG and ÖDG].” Wiener klinische Wochenschrift (2026). PMID: 42162485 ↗
L1GUIDELINECited in: Prognosis, Natural History, Special Populations and Prevention - [250]
Xiong Y, Huang M, Li H et al.. “Predictive Models for Hypoglycemia Risk in Haemodialysis Patients With Diabetic Kidney Disease: Systematic Review and Meta-Analysis.” Journal of clinical nursing (2026). PMID: 42246063 ↗
L1SR_OBSCited in: Prognosis, Natural History, Special Populations and Prevention - [251]
Poyatos-León R, Martínez-Vizcaíno V, Sequí-Domínguez I et al.. “The effect of myo-inositol supplementation on gestational diabetes mellitus prevention: a systematic review and meta-analysis.” American journal of obstetrics and gynecology (2026). PMID: 42242341 ↗
L1SR_OBSCited in: Prognosis, Natural History, Special Populations and Prevention - [252]
Domínguez-Navarro A, Lee M, Chen Y et al.. “Continuous glucose monitoring in older adults with diabetes across care settings: A systematic review.” Geriatric nursing (New York, N.Y.) (2026). PMID: 42167080 ↗
L2SR_OBSCited in: Prognosis, Natural History, Special Populations and Prevention